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ABSTRACT 
Asthma has been increasing in prevalence and morbidity, however it is unclear if the 
increase continues. Asthma has long been regarded as a single disease entity, but is 
now recognised as a heterogenic disease with different phenotypes. The overall aim 
was to investigate asthma and selected phenotypes in the population with regard to 
prevalence, medication use and differences in mechanism. 
In an epidemiologic study of 18 870 responders to a postal questionnaire, living in 
Gothenburg and Västra Götaland, the prevalence of physician-diagnosed asthma was 
8.3%. Compared with a study conducted 18 years ago on the island of Hisingen, the 
prevalence of most respiratory symptoms had decreased, while there was a small 
increase in asthma prevalence and a significant increase in allergic rhinitis. As an 
epidemiological proxy to severe asthma, multi-symptom asthma (MSA) was defined 
from responses to the questionnaire. The prevalence of MSA was 2% in the 
population and 24% among asthmatics. The definition was verified in a subgroup of 
subjects invited to our research clinic. MSA was associated with signs of more severe 
disease, such as lower lung function, more airway inflammation, hyper-
responsiveness and more severe health outcomes. Of subjects with MSA, 92% used 
asthma medication, compared with 61% of other asthmatic subjects. Inhaled 
corticosteroids were used by 70% of subjects with MSA, who also reported more 
frequent use of asthma medication. Selected participants from three phenotypes of 
asthma, and healthy controls were included in a proteomics study where several 
differences in protein expression patterns could be detected in nasal lavage fluid. In 
total 193 proteins was identified with a fold change of at least 1.3 as compared to 
healthy, these proteins represent different biological functions and pathways between 
phenotypes. 
We conclude that the previous increase in asthma prevalence has ceased and that 
respiratory symptoms are decreasing. MSA is common among asthmatics and is 
related to signs of more severe disease, hence MSA can be used an epidemiological 
marker of disease severity. Medication use is high in MSA, however under-treatment 
occurs. Further, quantitative proteomics on nasal lavage fluid can be used to identify 
differences in protein expression between asthma phenotypes, and possibly to detect 
differences in mechanism. 
Keywords: asthma, epidemiology, respiratory symptoms, medication, proteomics 
ISBN: 978-91-628-8573-1 
SAMMANFATTNING PÅ SVENSKA 
Det är sedan tidigare känt att förekomsten av astma och symtom från luftvägarna har 
ökat under 1900-talet, men det är oklart om ökningen fortsätter. Tidigare har astma 
betraktats som en sjukdom men det blir mer och mer tydligt att astma snarare utgörs 
av flera undergrupper. Dessa har olika bakomliggande orsaker och olika respons på 
behandling. Målet med avhandlingen, som består av 4 delarbeten, var att studera 
astma och några av dess undergrupper med avseende på förekomst, 
medicinanvändning och skillnader i bakomliggande mekanismer.  
Delarbete I består av en studie av befolkningen i Göteborg och Västra Götaland där 
18 087 personer besvarade en postenkät. Den visade att 8,3% har läkardiagnosticerad 
astma och att det är något vanligare jämfört med en studie på Hisingen, Göteborg 
1990. Förekomsten av luftvägssymptom har minskat medan allergisk hösnuva har 
ökat. Andelen rökare har nästan halverats mellan studierna, från 32% till 18%. Svår 
astma är problematiskt att studera i befolkningsstudier så därför definierades 
multisymptomatisk astma (MSA) som en markör. Förekomsten av MSA var 2 % i 
befolkningen och 24% bland astmatikerna. 
I delarbete II och III kontrollerades definitionen av MSA i en verifieringsstudie på 
vår forskningsklinik bland ett urval av deltagarna. Den visade att personer med MSA 
har sämre lungfunktion, mer inflammation i luftvägarna och fler tecken på svår 
sjukdom än personer med färre astmasymptom. Av personerna med MSA använder 
92% astmamedicin, jämfört med 61% av de med färre luftvägssymptom. De 
använder också inhalationssteroider i större utsträckning och de använder sin 
astmamedicin oftare och i högre doser.  
I delarbete IV studerades utvalda deltagare som representerade tre undergrupper av 
astma samt friska kontroller i en studie där kvantitativ proteomik användes för att 
kartlägga proteinuttryck i nässköljvätska. Flera skillnader i proteinuttryck kunde 
identifieras mellan undergrupperna och friska. Totalt var 193 proteiner upp- eller 
nedreglerade med en faktor på minst 1,3 jämfört med friska. Dessa proteiner 
representerade olika biologiska funktioner mellan undergrupperna.  
Från avhandlingen dras slutsatserna att den tidigare ökningen i förekomsten av astma 
nu har upphört och att förekomsten av luftvägssymptom minskar. MSA är vanligt 
bland astmatiker och är kopplat till tecken på svårare astma, alltså kan MSA 
användas som en markör för svårighetsgrad av astma i befolkningsstudier. 
Användningsgraden av astmamedicin är hög i gruppen med MSA, men 
undermedicinering förekommer. Vidare dras slutsatsen att kvantitativ proteomik kan 
användas för att hitta skillnader i proteinuttryck mellan undergrupper av astma och 
möjligen för att identifiera skillnader i bakomliggande mekanismer. 
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1 INTRODUCTION 
This thesis is based on material from the West Sweden Asthma Study 
(WSAS) conducted in Västra Götaland between winter of 2008 and spring of 
2012. WSAS is an epidemiological study focused on respiratory diseases and 
aims to reach from basic to clinical epidemiology and from study of 
populations to studies of mechanisms. This thesis starts in an epidemiological 
survey of the general population and ends in a proteomics analysis of selected 
phenotypes of asthma thus taking advantage of the strengths in the WSAS.  
This thesis book will give an introduction to the research behind the parts 
included in the thesis, as well as short descriptions of the methods and 
results. Finally there is a discussion of methodology and main results. 
1.1 Epidemiology of asthma 
1.1.1 Reasons for conducting epidemiological 
studies  
Epidemiological studies can be divided into two main categories, 
retrospective and prospective. Retrospective studies are studies of 
occurrences that have already happened. Prospective studies are studies of 
occurrences that may happen in the future. Studies can be cross-sectional 
(one time-point) or longitudinal (multiple time-points) and be case-control or 
cohort studies. 
A cross-sectional study compares groups of people in terms of their current 
health and exposure status, and assesses their similarities. It is also common 
that cross-sectional studies inquire on medical and exposure history. A cross-
sectional study is relatively easy to conduct as the investigator do not need to 
wait for the outcome to occur or try to estimate the occurrence of a risk factor 
several years earlier. The main disadvantage of cross-sectional studies is the 
inability to infer causation; however cross-sectional studies can be used to 
identify possible associations. An important limitation of this approach is that 
it does not allow for changes over time, and thus cannot accommodate 
diseases that take time to develop. 
A cohort study follows a group of people over time to investigate what will 
occur in terms of what is studied. A cohort study can also have sections that 
are cross-sectional, where a representative group of a population is studied to 
determine the occurrence of disease and potential risk factors. A longitudinal 
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cohort study is most useful for relatively common diseases and is a desirable 
design because exposure precedes the health outcome, a condition necessary 
for determining causation. It is less subject to bias because exposure is 
evaluated before the health status is known. The cohort study is also 
expensive, time-consuming and the most logistically difficult of all the 
studies. The commonality of the disease and how often a risk factor occurs 
will determine how large the cohort needs to be for sufficient power for risk 
factor analyses. A high participation rate is important in longitudinal studies 
as not to introduce bias due to non-representative participants.  
In a case-control study, one investigates the prior exposure of individuals 
with a particular health condition and those without it, to infer why certain 
subjects, the "cases," become ill and others, the "controls," do not. The case-
control study is an advantageous design when rare health outcomes are 
studied as it is not necessary to follow very large cohorts over extended time 
periods. Case-control studies are generally easier, quicker and less expensive 
than a cohort study. A great disadvantage of case-control studies is a greater 
potential for bias, as cases and controls are selected after the outcome and 
risk has occurred the possibility to inadvertently favor certain cases. Once 
cases are selected based on an outcome, the subjects cannot be analyzed for 
other outcomes as they could in a cohort study. 
 
1.1.2 History of asthma epidemiology 
The standardization of modern respiratory questionnaires started in 1950s in 
the United Kingdom. The respiratory research was focused on bronchitis and 
as a result of different observers, diverging results were obtained regarding 
the prevalence of bronchitis [1]. This divergence motivated the development 
of standardized questionnaires about respiratory symptoms [2-4]. The British 
Medical Research Council (BMRC) Committee on the Aetiology of Chronic 
Bronchitis finalized the “Respiratory Symptoms Questionnaire” (BMRC-Q) 
in 1960 [5], a questionnaire that had been validated by Fletcher and co-
workers [3]. Although developed 50 years ago, the BMRC-Q is still used in 
original or, most often, modified versions. At the same time, a strict 
definition of chronic bronchitis was suggested, a definition that researchers 
agreed upon [6]. The definition was later adopted by the World Health 
Organization (WHO) [7] and in most aspects by the American Thoracic 
Society (ATS) [8].  
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An important aim of the BMRC-Q was to avoid interviewer bias [2]. 
However, in early stages of bronchitis the standardized inquiry of symptoms 
still caused uncertainty, and interviewer bias could still not be completely 
avoided. Further, performing interviews was expensive and resource 
consuming. Thus, self-administrated questionnaires were developed. The first 
well validated self-administrated respiratory questionnaire was developed for 
the Tucson studies in Arizona, USA [9]. The authors concluded that the self-
administrated questionnaire was a useful instrument for epidemiological 
studies of airway disorders although relatively large differences were found 
in outcomes of questions about symptoms common in asthma. Later studies 
has also shown that outcomes of self-administered questionnaires differ from 
structured interviews [10]. 
The first British questionnaires were focused solely on bronchitis, and 
questions about asthma (“Have you ever had bronchial asthma?”) and attacks 
of shortness of breath with wheezing were included in the BMRC-
questionnaire in 1966. In the 1970s, several questionnaires were developed in 
the USA including questions for identifying asthma. The most important 
included the National Heart and Lung Institute questionnaire [11], which was 
a modified BMRC-Q. That questionnaire was further developed by the ATS 
and the National Institute’s Division of Lung Diseases, to a new 
questionnaire known as the ATS-Q with more detailed questions on asthma 
[12]. By that time, the new self-administered Tucson-questionnaire was 
already validated and used in a large scale epidemiological survey [9]. 
In Europe, the BMRC-Q questionnaire was translated in 1962 to French, 
German, Italian and Dutch and further developed by adding additional 
questions about asthma to form the European Community for Coal and Steel 
(ECCS) questionnaire [13]. Several national questionnaires for identifying 
asthma, chronic bronchitis and respiratory symptoms, were developed in 
Europe during 1970s and 1980s, most of them expanded versions from the 
BMRC-Q. However, there was still an urgent need for a standardized 
questionnaire that could be used in several languages and countries. With the 
focus on asthma, the International Union Against Tuberculosis and Lung 
Diseases (IUATLD) Bronchial Symptoms Questionnaire was developed as a 
result of a large international cooperation in a longer (1984) and a shorter 
(1986) version [14]. The widely used European Community Respiratory 
Health Survey (ECRHS)-Q is a short version of a modified IUATLD-Q [15]. 
In turn, the ECRHS-Q was edited to form the recent Global Allergy and 
Asthma European Network (GA2LEN)-Q. A specific questionnaire for the 
study of asthma and allergies among children, the International Study of 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
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Asthma and Allergies in Children (ISAAC) questionnaire has also been 
developed [16] 
 
1.1.3 Validation of respiratory questionnaires 
In the 1960s and 1970s when new questionnaires were developed the 
validation procedures consisted mainly of comparisons with previously used 
questionnaires [9, 17]. Comparisons of structured interviews and self-
administered questionnaires were performed in the 1970s and the self-
administered questionnaire was found to be valid [9, 18, 19]. Questions on 
wheezing, shortness of breath and breathlessness had a strong agreement of 
about 0.9, while questions on cough, phlegm, dyspnoea and physician-
diagnosed diseases had a slightly weaker agreement of about 0.8. 
From the different validation procedures it can be concluded that results 
based on self-administrated questionnaires differ from structured interviews 
[9, 10, 19]. Furthermore, translations create variability [14, 20], particularly 
the translation of “wheeze”. Responses to self-administered questionnaires, 
before and after oral information on asthma symptoms, results in divergent 
results with poor agreement with kappa statistics below 0.4 [21]. The 
agreement may also vary depending on the subjects smoking habits and 
educational level [20]. The best way to validate a questionnaire on asthma 
seems to be a combination of clinical examinations and a clinical assessment 
of the symptoms [22, 23].  
 
1.1.4 Prevalence trends of asthma and 
respiratory symptoms 
Asthma affects approximately 300 million people all over the world and it is 
estimated to increase to 425 million in the next 10-15 years [24, 25]. Asthma 
prevalence has mainly been studied among children [26-32], with the ISAAC 
study as the most prominent example [16]. The studies have shown a marked 
increase in asthma prevalence with a possible decrease during the last 10-20 
years. 
The Global Initiative for Asthma (GINA) reports asthma prevalence to range 
from 5-18% in the world [25], with the prevalence in Sweden at about 9% 
[33]. There are several cross-sectional studies on asthma prevalence and 
symptoms common in asthma, and several attempts have been made to 
Linda Ekerljung 
 
 
5 
determine whether asthma prevalence among adults is changing [26, 33-40]. 
Several studies report an increase in asthma prevalence among adults during 
the second half of the 20th century [26, 39]. During the last 20 years the 
increase seem to have plateaued, at least in Western Europe and Australia 
[26, 33, 38] however, increased prevalence is still observed [39, 40]. In 
contrast, the prevalence of asthma is still increasing in several developing 
countries [27]. In general, the prevalence is higher among women and among 
younger subjects [39, 40].  
The increase in prevalence that some studies report may be a consequence of 
patients with a milder disease being diagnosed with asthma today compared 
with previously [33, 41]. The observed changes in asthma prevalence may be 
partially explained by systematic errors arising from changes in diagnostic 
practice due to a lack of standardized definitions for asthma [29]. 
Furthermore, the increased awareness of asthma in the public may result in 
increased self reporting, contributing to a further escalation in asthma 
prevalence.  
 
1.1.5 Studies of asthma incidence 
There are very few studies of asthma incidence. There has likely been an 
increase in asthma incidence during the last 35-45 years as indicated by 
higher incidence rates being reported in more recent studies compared to 
older [42, 43]. A recent comparison analysis of studies conducted over 20 
years showed that the increase in asthma incidence has ceased in Sweden [41, 
44, 45]. The incidence rate varies extensively between studies, ranging from 
0.4-11/1000/year. Beside a true difference in incidence rate, this broad range 
could be due to methodological differences. In Sweden the incidence rate of 
physician-diagnosed asthma among adults is about 2/1000/year. 
 
1.1.6 Risk factors associated with asthma 
There are several risk factors for asthma, with the most important being 
heredity, allergic sensitization, socio-economic status, and environmental 
factors such as occupational exposures and smoking.  
Type 1 allergy, atopy   
The allergic reaction is caused when an allergen interacts with a specific-IgE 
antibody causing the immune response to react. Allergic rhinitis (AR) is the 
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most common immunological disorder and is estimated to affect 500 million 
people worldwide [46, 47]. AR and asthma have common physiological, 
pathological and epidemiological features [48] and AR is commonly found in 
subjects with asthma and is an important risk factor [49], with up to 80% of 
asthmatics suffering from AR [50]. In Sweden, sensitivity to pollen often 
results in AR, while subjects with asthma often are sensitized to furred 
animals [51]. The allergen(s) that causes AR and asthma varies between 
countries. In countries with a cold, dry climate, asthma is commonly 
associated with furred animals and somewhat less to grass and pollen, while 
mites, moulds and cockroaches commonly is associated with asthma in 
countries with temperate or tropical climates [52-57]. Allergic sensitization 
plays a minor role in the development of asthma among middle-aged and 
older subjects. 
Family history of atopic disease 
In addition to allergic sensitization, having family history of atopic disease is 
the strongest risk factor for the development of asthma [58-60]. The risk of a 
child developing asthma increased three times if one parent had asthma and 
was ten times higher if both parents had asthma [58]. 
Gender 
The gender distribution for asthma is different depending on age, with the 
prevalence of asthma being higher in boys, while in adults, asthma is more 
prevalent among women [33, 58, 61]. Lower quality of life and problems 
with asthma control have also been associated to female gender [62]. The 
gender related differences might be caused by some women being 
hypersensitive to their sex hormones, or by other hormonal processes [63]. 
Socio-economic status  
Low socio-economic status is often associated to poorer health [64]. Socio-
economic status can be classified using income, occupation and educational 
level, or a combination of these [64-66]. Low socioeconomic status has been 
reported to have a variety of associations with asthma; positive, negative and 
no association. [64-73]. Low socioeconomic status, defined as low 
educational level, was related to a higher incidence and prevalence of asthma 
in the ECRHS [65]. An increased risk of prevalent and incident asthma and 
respiratory symptoms has also been reported in manual workers [64, 66, 69], 
especially those belonging to the socio-economic group of manual workers in 
service [69]. Increased asthma severity has been reported in low socio-
economic classes [73]. There are many possible confounders in the observed 
association between socio-economic status and asthma or respiratory 
symptoms. The confounders include occupational exposure, smoking, 
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obesity, life stress, ethnicity, exposure to housing and outdoor pollution and 
environmental tobacco smoke [72, 74-76]. 
Occupational exposure 
During the last decade, occupational asthma has been identified as a large 
problem in public health. Studies have shown that approximately 15-20% of 
adult asthma can be explained by occupational exposure [77]. However, the 
association might be an under-estimation due to the “healthy worker” effect 
[78]. The “healthy worker” effect is when subjects with asthma choose 
occupations that are free of certain exposures that might worsen their 
respiratory health. It might also mean that employers within certain 
occupations do not hire subjects with asthma. A recent study showed that 
those with allergic rhinitis during adolescence are less likely to choose 
occupations classified as having a high risk of incident asthma [79].  
Common occupations that are associated to occupational asthma are bakers, 
hairdressers, laboratory workers, welders, cleaners, wood workers and 
occupations that are related to exposures to dust, gas and particles [80]. In 
addition to occupation related exposures, there are other factors in the work 
place that can worsen respiratory symptoms, these include colleagues who 
smoke or use perfume, cold, physical exertion and psycho-social factors [81].  
Tobacco smoke  
Smoking is decreasing in large parts of the Western world. In Stockholm, 
Sweden the prevalence of smoking decreased from 31% in 1996 to 18% in 
2006 [33]. In a recent European study the prevalence of smoking was lower 
among subjects with asthma compared to subjects without asthma [82]. 
While smoking is the most important risk factor for respiratory symptoms, 
the association between asthma and smoking is less clear [83, 84]. Former 
smoking and ever smoking has been associated to asthma in several cross-
sectional studies [85-88], while others have shown no association [89]. 
Significant association is more often found in prospective studies [43, 90-92]. 
A lack of association between smoking and asthma could possibly by due to 
the healthy smoker effect. Environmental tobacco smoke has been associated 
with all types of respiratory symptoms and asthma, especially in females [75, 
93, 94]. 
 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
8 
1.2 Asthma 
1.2.1 Bronchial hyper-responsiveness  
Bronchial hyper-responsiveness (BHR) is a common feature in asthma and 
results in temporary bronchoconstriction and increased symptoms [95]. It is a 
condition in which the airways react with an exaggerated bronchoconstriction 
in response to stimuli [96]. In Sweden, it has been clinical praxis to use BHR 
to verify asthma when the anamnesis is inconclusive and cannot be verified 
with variable peak expiratory flow or a positive bronchodilatation test [97]. 
The airways of asthmatics respond with a greater constriction to a certain 
stimulus than the airways of healthy subjects. It is a characteristic feature of 
asthma and can be demonstrated in almost all patients with a clinically 
relevant asthma [98, 99]. The presence of BHR is often determined using 
direct challenge tests using methacholine or histamine. These are highly 
sensitive, cheap and easy to perform but are not specific to asthma [99, 100]. 
There is a considerable variability in the intensity of BHR between patients 
with asthma, and the level of reaction varies also for an individual with 
asthma depending on exacerbations, allergen exposure and occupational 
exposures. The effect of steroid use on BHR is limited among severe 
asthmatics, even though the underlying inflammation is reduced [99]. 
However, decrease in hyper-reactivity has been demonstrated when 
asthmatics have been free from symptoms and exacerbations during an 
extended time period, as a result of maintenance treatment [101]. The 
prevalence of BHR in different populations may vary considerably and is 
probably due to a wide variety of methods of measure and definitions of 
BHR. An epidemiological study in Finland found the prevalence of BHR to 
be about 20% using both methacholine and histamine [102]. Meanwhile, a 
Swedish study using another methacholine based method, found a prevalence 
of about 13% [103].  
 
1.2.2 Defining asthma in epidemiological studies 
Assessment of asthma is impaired by the lack of a clear and definite 
standardization of definitions of asthma and symptoms. Indeed, there is no 
single test or gold standard for defining or identifying asthma [22, 104]. The 
current definitions of asthma have four main parts: respiratory symptoms, 
bronchoconstriction, airway inflammation, and BHR. In the 1980s several 
researchers regarded BHR as a gold standard for asthma [96, 105]. A 
questionnaire was developed to identify asthma if possible only by symptoms 
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[14], the questionnaire was validated against BHR [14] and another 
questionnaire [106]. However, the validation showed that asthma could not 
be identified by solely using symptoms. A question of “Has a doctor ever told 
you have asthma” (physician diagnosed asthma) has a good specificity [107-
109], especially when combined with symptoms and medication use in the 
last year. It is important in epidemiological studies of asthma to always 
clearly state the definition used for asthma, and preferably also the exact 
questions that were used [110]. 
 
1.3 Asthma – not a single disease entity 
1.3.1 Phenotypes of asthma 
Today there is an ongoing debate on the importance clinical phenotypes of 
asthma. Studies are performed using hypothesis driven phenotyping or 
phenotyping based on cluster analysis. When cluster analyses are performed 
it is important to use a study sample that is representative of the population, 
and the included variables have great effect on the results. Sub classification 
seems no less important when we consider that other important diseases such 
as arthritis and anemia are no longer named by their syndromes but by 
specific subtypes. Asthma, which affects about 10% of the population, is still 
referred to as the broad syndrome of asthma. A discussion about a new 
taxonomy for the obstructive airway diseases has been initiated by Beasley 
and coworkers [111].  
1.3.2 Severe asthma  
The global Asthma Insights and Reality (AIRE) survey reported that 18% of 
asthmatics have a severe asthma [112]. Severe asthma causes the most 
significant economical burden of asthma, despite representing a minority of 
those with asthma [113, 114]. It poses a great burden both on the individual 
and on society, as it is associated with an impaired quality of life [115], 
lifestyle restrictions [116], high socio-economic costs [114], increased 
morbidity with need of emergency care, increased risk of hospitalization and 
death [112, 117]. Many patients continue to have symptoms and lifestyle 
restrictions despite treatment and require emergency care due to asthma 
[112]. Clinical studies suggest that severe asthma is more common among 
women [112, 118] and when compared with asthma in general, a greater 
proportion have presence of neutrophilic inflammation [118, 119]. Severe 
asthmatics often have increased BHR and airway inflammation, impaired 
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lung function, frequent night-time awakenings and dyspnoea. Airway 
symptoms upon intake of aspirin is also more common among severe 
asthmatics [118] and asthmatics with concurrent rhinitis are at a higher risk 
for hospitalization and have a higher cost of asthma medication [120]. 
Severe asthma is difficult to define, the terminology has not been 
standardized and terms are still used interchangeably. Definitions are 
commonly based on the required need of asthma medication to achieve a 
controlled disease [121].. Traditionally severe asthma has been synonymous 
with asthma having frequent symptoms, despite the highest level of treatment 
[118, 122, 123]. Asthma has also been defined based on level of control 
rather than symptom severity [124, 125]. The level of asthma control is 
important, as it affects exacerbation frequency and quality of life [115, 126-
128]. The GINA 2006 revision defines asthma by level of control based on 
symptoms, need of medication, exacerbations and lung function [124]. WHO 
defines severe asthma as “uncontrolled asthma” resulting in risk of frequent 
severe exacerbations and or adverse reactions to medications and/or chronic 
morbidity” [129]. According to the recent WHO definition, severe asthma 
includes three groups: untreated severe asthma, difficult-to-treat severe 
asthma and treatment-resistant severe asthma. In this definition the use of 
asthma medication is not included.  
 
1.3.3 Aspirin intolerant asthma 
First described in 1902 by Hirschberg [130], the mechanism causing adverse 
respiratory reaction to aspirin still remains to be elucidated. Hypersensitivity 
to aspirin can have several manifestations including asthma, rhinosinusitis, 
urticaria and anaphylaxis [131]. In 1968, Samter and Beers focused on the 
coexistence of aspirin sensitivity, nasal polyposis and chronic rhinosinusitis 
[132], the phenomenon is now known as Samters’ triad. In aspirin induced 
asthma (AIA), breathing problems arise following ingestion of acetylsalicylic 
acid or non-steroidal anti-inflammatory drugs (NSAIDs), usually within three 
hours. AIA is commonly characterized by chronic rhinosinusitis with up to 
26% of subjects with nasal polyps also suffering from AIA [133, 134]. The 
prevalence of AIA is 0.5-1.9% in the general population [131], and 4.3-11% 
of asthmatics [135, 136]. The pathogenesis is still unknown but involvement 
of the arachidonic acid metabolism, with inhibition of cyclooxygenase-1 
(COX1) and an increase in inflammatory mediators such as cysteine 
leukotrienes (CL) is likely [137, 138]. Prostaglandin (PG) E2 has been 
proposed to have a crucial role as PGE2 normally act as an inhibitor on 
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excessive production of CLs [133]. COX is a group of enzymes that 
metabolize arachidonic acid to PGE, thromboxanes and prostacyclin. 
Deprivation of PGE2 may lead to activation of inflammatory pathways. AIA 
may be related to the inhibition of the COX enzyme but blockage of the CL 
pathway by specific inhibitors such as 5-lipooxygenase inhibitors do not 
completely protect against AIA [139, 140]. A decrease in inflammatory 
suppressors has also been suggested. To properly diagnose hypersensitivity to 
aspirin and NSAIDs an understanding of the underlying mechanism is 
necessary. 
1.4 Use of asthma medication  
In Western societies, prevalence of asthma reflects the prevalence of users of 
asthma medication [141, 142], and over the past decades an obvious increase 
in asthma medication has been observed [143, 144]. Issues of non-adherence 
are well recognized in asthma and low adherence is associated with poor 
asthma control, increased mortality, decreased quality of life, increased 
hospitalization rates and increased risk of exacerbations [112, 115, 117, 145, 
146]. Still, many patients with persistent symptoms consider their disease 
“well controlled” [112, 147] which could explain part of their non-adherence. 
In the AIRE-study [112], a low usage of preventive medication, with many 
patients having to resort to quick-relief medication, indicative of poor asthma 
control, was demonstrated. There was also a poor correlation between the 
level of symptoms and perceived asthma control. People with severe asthma 
are also prone to anxiety and depression, which is also associated with non-
adherence to treatment regimens [148-150], and an overestimation of 
adherence has been demonstrated [151]. The level of asthma control often 
falls short of the management goals with many patients being severely 
undertreated, both among mild and severe asthmatics [112, 147, 152-154]. A 
lower adherence in subjects with more severe disease and an overestimation 
of adherence has reported [112, 151, 155, 156]. Gamble et al [155] 
demonstrated that 35% of asthmatics had non adherence as main cause of 
difficult-to-treat asthma. Studies of prescription refill data have shown 
considerable discrepancies between self-reported adherence and prescription 
refills where adherence was more overestimated in severe asthmatics, 
implying that severe asthma is in part due to poor adherence to asthma 
medication [151, 156]. Studies of non-adherence according to gender have 
been inconclusive with some showing no gender differences [157, 158] and 
some showing a lower adherence among women [159]. 
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1.5 Chronic rhinosinusitis 
Chronic rhinosinusitis (CRS) is an inflammatory condition of the mucosa of 
the nose and paranasal sinuses that persists for at least 12 weeks [160]. The 
prevalence of self-reported CRS according to the European Position Paper on 
Rhinosinusitis and nasal Polyps (EP3OS)-criteria was 6.9-27.1% in a 
European comparison [161]. There are two forms of CRS; with nasal polyps 
(CRSwNP) and without (CRSsNP), with CRSsNP being most common 
[160]. The pathophysiology of the two phenotypes is largely unknown, 
however some evidence suggests that CRSsNP is mainly Th1-polarised, with 
interferon-γ more prominent than interleukin (IL)-5, while CRSwNP is 
mainly Th2-polarised [160]. In CRSwNP, eosinophils are the main 
contributor of inflammation, while myeloperoxidase and IL-8 concentrations 
are increased in CRSsNP indicating that in addition to eosinophils, 
neutrophils are also involved in the pathogenesis [162, 163]. Transforming 
growth factor β1 (TGF-β1) has a key role in tissue remodeling in CRS with 
expression reported to be significantly higher in patients with CRSsNP versus 
control subjects [164]. TGFβ signaling also contributes to the regulation of 
expression of matrix metalloproteases and their natural tissue inhibitors.  
 
1.6 Proteomics 
1.6.1 Reasons for studying the proteome 
One definition of a proteome is “a set of proteins being expressed in a given 
type of cell or organism at a given time under defined conditions”. This 
implies that the proteome is ever changing and proteomics of a human 
sample is a snapshot of that individuals’ proteome at the time of sampling. It 
is becoming increasingly clear that while the study of the human genome has 
its benefits, it is not enough to understand differences and changes in 
complex diseases such as asthma. There has been many studies aimed at 
identifying asthma susceptibility genes but replication of the results has been 
difficult and the clinical relevance is uncertain[165]. There are many factors 
that influence which genes are being expressed at a given time, and how 
these genes are being subject to post-translational modifications. Further, the 
DNA sequence alone does not reveal biological function and one gene can 
code for several proteins by gene rearrangements and RNA splicing. The 
proteome varies between tissues, between different cell types, with 
developmental stage and depending on the environment and disease. 
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1.6.2 Asthma proteomics 
Proteomics of human samples poses several issues. The natural variation is 
much higher compared with animal models or cell cultures and is further 
increased by external factors such as sampling, storage and processing [166]. 
While proteomics and quantitative proteomics has been used successfully in 
other fields, the area is still largely unexplored in regards to asthma [167-
171], possibly due to the complexity of disease. Allergic airway 
inflammation has been explored in animal models of asthma, both with [172, 
173] and without [174, 175] the influence of glucocorticoid treatment. Very 
few of these models have been confirmed in human studies [176]. Cell 
cultures, particularly from bronchial brushings has been used to explore 
differences between asthmatics and healthy, airway surface liquid with and 
without cytokine stimulation has been explored [177, 178]  as well as 
fibroblast in asthmatic airways [179-181]. Biological fluids, such as 
bronchoalveolar lavage fluid (BLF), nasal lavage fluid (NFL) and sputum, 
have been used to compare asthmatics and healthy subjects [182-184], effects 
of airway challenge [185, 186] and effects of exposures [187, 188]. 
Proteomics on plasma from asthmatics has shown differential expression in T 
lymphocyte proteins [174]. 
 
1.6.3 Separation techniques  
In this thesis, reversed phase liquid chromatography (RP-LC) was used to 
enhance sensitivity prior to mass spectrometry (MS) analysis. This procedure 
is often used as it reduces the complexity of the sample. In RP-LC samples 
are loaded onto columns packed with solid phase adsorbents, carrying 
hydrophobic groups, generally C18 is used for peptide analysis, that bind to 
the peptides through hydrophobic interaction, while salts and other water 
soluble impurities are washed away. The peptides are eluted by applying a 
gradient of an organic solvent (e.g. acetonitrile) and the sample containing 
fractions are then analyzed separately in the MS. 
 
1.6.4 Mass spectrometry 
MS is a key technique in proteomic analysis providing accurate mass 
measurements of small quantities of proteins, peptides and peptide fragments. 
Analysis of peptide fragments give information of the amino acid sequence 
and modifications. Three components are generally present in all mass 
spectrometers: an ion source, a mass analyzer and a detector. Sample 
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molecules are introduced into the ion source where they are converted into 
gas phase ions. The mass analyzer separates the ionized species according to 
their mass to charge (m/z) ratio and the detector records an ion current of the 
separated analytes. Results are then plotted in the mass spectra, as the ion 
current against m/z. A tandem mass spectrometer (MS/MS) has more than 
one analyzer or the same analyzer can be used for both MS and MS/MS. A 
collision cell, where selected molecules are admitted to collide with an inert 
gas, produces the fragments analyzed in the second MS. A peptide is selected 
based on information from the primary ions in the MS (MS1). Peptides of the 
selected m/z are then passed onto a collision cell where they are further 
fragmented to produce daughter ions which are analyzed in the second MS 
(MS2). Each peptide will only be fragmented once but the site of cleavage 
will vary between peptides with the same m/z. There are a number of 
different types of mass spectrometers employed in proteomic research. 
Electrospray ionization 
The ionization method used in this thesis is nano electrospray ionization 
(ESI) [189] since it enable production of intact gaseous ions of large 
biomolecules. The inventor of the ESI, John Finn, was awarded with the 
Nobel Prize in chemistry in 2002. With ESI the sample solution is sprayed at, 
atmospheric pressure, from the tip of a thin capillary and a strong electric 
field is applied between the capillary and a counter electrode and a fine spray 
of charged droplets is produced.  
Quadrupole mass filters 
A quadrupole mass filter separates ions according to their m/z by utilizing the 
stability of their trajectories in an oscillating electrical field. The field is 
created by a combination of radio frequencies and direct current voltages 
with only one mass permitted to pass at one time. The remaining masses 
collide with one of the four metal rods, not reaching the reactor. The LTQ is a 
linear ion trap that use a three-dimensional quadrupole field to trap and mass-
analyze ions, which have a very good sensitivity and is fast, however the 
resolution is not so high. Furthermore the LTQ can carry out fragmentation 
reactions allowing high-resolution MS/MS experiments.  
Orbitrap mass analyzers 
The Orbitrap was invented by Alexander Makarov in the late 1990s [190]. In 
an Orbitrap, ions are trapped in an electrostatic field in which the ions orbit 
around a central electrode while at the same time oscillating along the central 
axis of the electrode. The oscillation ion induces an image current into the 
two outer halves of the Orbitrap, which are detected using a differential 
amplifier. The Orbitrap measure frequency (how fast the ion spin) which is 
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unique to the specific m/z. Ions of only one mass generate a sine wave signal 
which is converted to m/z  spectra using a fast Fourier transform algorithm. In 
this thesis an LTQ Orbitrap Velos (Thermo Fisher Scientific Inc., Waltham; 
MA, USA) instrument was used. 
 
1.6.5 Quantitation by mass spectrometry 
There are several ways to quantify samples in mass spectrometry based 
proteomics. A common approach is stable isotope labeling which can be done 
in vivo or in vitro. In vitro labeling involves the incorporation of stable 
isotopic tags onto selective sites on the peptides, such as the amine group of 
the N-terminus. Depending on the selected method, up to eight samples can 
be quantified at the same time using isobaric tag for relative and absolute 
quantification (iTRAQ) or tandem mass tag (TMT) labeling techniques of the 
peptides.  
A mass tag for isobaric labeling has three parts; firstly, a group that will react 
with the peptide that is to be labeled, secondly, a part that act as a mass 
balance so that all tags have the same mass in the first MS, and finally, a 
mass reporter that has a different mass between the labels (Figure 1). The 
TMT isobaric tags have identical structures that covalently attach to the 
amino-group of lysine and the N-terminal of the peptides. During MS, the 
labeled peptides cannot be distinguished from each other and thus are 
progressed to the second MS as one m/z. In the MS/MS, each tag produces a 
unique reporter ion signature, enabling quantification by comparing 
intensities of the reporter ions. If several sets are being analyzed within the 
same experiment, one of the tags is used to label a pool consisting of small 
amount from each sample, making comparisons between sets possible.  
Figure 1. Schematic of a TMT mass tag 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
16 
1.6.6 Proteins identification 
Depending on the used MS technique, different methods for the identification 
of proteins is used. When MS/MS has been used amino acid sequence 
analysis is usually applied and identification of proteins is done by matching 
mass spectrometric data to databases containing known protein sequences.  
Amino acid sequence analysis using tandem mass 
spectrometry  
In MS/MS, a spectrum is created that is more or less unique for the 
investigated peptide [191]. This is achieved by isolating a single peptide 
precursor and inducing fragmentation along the peptide bonds. The identified 
masses are then compared with theoretical fragmentation patterns of proteins 
in a database search. 
In the LTQ Orbitrap Velos fragmentation can be done using collision induced 
dissociation (CID) or higher-energy C-trap dissociation (HCD). The CID 
process includes multiple low-energy collisions of the peptide precursor ion 
with an inert gas, usually argon, which finally leads to dissociation of the 
precursor ion [192]. The HCD process involves fragmentation of ions in a 
collision cell and then the ions are transferred back to the C-trap for analysis 
in the Orbitrap [193]. Which protein database that is used will affect the 
outcome, in this thesis UniProtKB Swiss-Prot was used. UniProtKB Swiss-
Prot is non-redundant, manually curated and cross-referenced.  
 
1.6.7 Interpreting the results 
Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) is a web based licensed bioinformatics 
tool which takes information from the Ingenuity® Knowledge Base 
(Ingenuity® Systems, www.ingenuity.com). The Ingenuity® Knowledge Base 
is a repository of biological interactions and functional annotations created 
from millions of individually modeled relationships between proteins, genes, 
complexes, cells, tissues, metabolites, drugs and diseases. It is manually 
reviewed and updated regularly. It allows the user to explore biological 
functions, networks and pathways associated to the analyzed dataset.  
Protein analysis using gene ontology 
The Protein Analysis THrough Evolutionary Relationships (PANTHER)  
Classification System [194] is a web based resource that classifies genes by 
their function. The classification is performed by expert biologist who uses 
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scientific evidence and evolutionary relationships to describe the gene 
products in terms of biological process, cellular components and molecular 
functions. PANTHER is part of the Gene Ontology (GO) Reference Genome 
Project [195]. 
As for PANTHER, GO Term Finder [196] is part of the GO consortium in 
which gene products may be annotated to one or more GO nodes. It can be 
used to draw conclusions from microarray and other biological data, 
calculating the statistical significance of each annotation and thus, can 
identify the GO terms significantly enriched in a submitted list of genes. 
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2 AIM 
The aims of this thesis were: 
1. To estimate the current prevalence of asthma and respiratory 
symptoms in West Sweden. 
 
2. To evaluate if the prevalence of asthma and respiratory 
symptoms are still increasing. 
 
3. To investigate if markers of severe asthma can be identified 
by a postal survey. 
 
4. To investigate patient reported use of asthma medication in 
West Sweden. 
 
5. To investigate if differences in protein expression between 
asthma phenotypes can be identified in a non-invasive 
samples.  
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3 METHODS AND MATERIALS 
3.1 Study area 
The region of Västra Götaland 
reaches from the northern part of 
Sweden’s west coast to the lakes 
of Vänern and Vättern in the 
central part of Southern Sweden 
(Figure 2) and is referred to as 
West Sweden in the papers 
included in this thesis. The region 
is very diverse with rural areas, 
small and medium sized towns 
and a big city. In the beginning of 
2008, when this study was 
initiated 1.6 million people were 
living in the county, representing 
1/6th of Sweden’s population. 
Gothenburg is situated on the 
west coast and is the second 
largest city in Sweden with 
700 000 living in the city or in the 
surrounding urbanized area. The 
population in the area is 
representative of Sweden in 
regards to age and gender 
distribution. The climate is 
oceanic according to the Köppen 
climate classification with warm 
summers, mild winters and high 
humidity. The average 
temperature is between 15 to 
16°C in July and between -1 to -4 
degrees in January. The average 
precipitation 500-1000 mm/year 
[197].            
Figure 2.  Sweden with the study area of 
Västra Götaland in darker grey. Modified 
from a image by Lokal_Profil under 
license agreement CC-BY-SA-2.5 
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3.2 Study design and study population 
The first part of the WSAS took place in 2008 when a postal questionnaire 
was mailed to 15 000 randomly selected subjects living in the metropolitan 
area of Gothenburg and 15 000 randomly selected subjects living in 
remaining study area. The population was stratified by 10-year age groups 
and gender to best represent the population in Västra Götaland. Of the 
randomly selected subjects, 782 could not be traced, were deceases or were 
unable to participate. Paper I is based on the 18 087 subjects who responded 
to the questionnaire.  
From responders to the questionnaire, a random sample of 2000 was selected 
for clinical examinations. In addition, all subjects who reported physician-
diagnosed asthma or reported every having asthma and either use of asthma 
medication, wheeze or attacks of shortness of breath during the last year were 
also included in the clinical cohort. In total, 3536 subjects were included, of 
which 1736 had reported asthma in the questionnaire. Paper II includes data 
from the 18 087 responders to the questionnaire and clinical data from the 
843 subjects who had participated in the clinical examination between 
February 2009 and December 2010. Paper III includes data from the 1755 
subjects who had participated in clinical examinations between February 
2009 and December 2011. Paper IV included 36 well characterized subjects 
who had participated in the clinical examinations and had successfully given 
NLF, thus enabling separation of three phenotypes of asthma and a healthy 
control group. A schematic of the study design is shown in Figure 3. 
The clinical study was completed in May 2012 and included 2002 subjects, 
1172 from the random sample and 830 from the asthmatic group. Of 
participating subjects from the random sample, 132 were considered 
asthmatic based on their responses in the questionnaire survey which meant 
that a total of 962 asthmatic subjects had attended the clinical examinations.  
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Figure 3. Study design of the West Sweden Asthma Study. 
3.3 Postal questionnaire 
The questionnaire consisted of two parts that were included in a folder mailed 
to the selected subjects, together with a pre paid response envelope. The 
participants could also choose to respond by using a web based questionnaire 
with unique user names and passwords. 
The first part of the questionnaire was the Obstructive Lung disease In 
Northern Sweden (OLIN)-questionnaire [198], which has been extensively 
used in Sweden and within the FinEsS-studies (epidemiological studies of 
obstructive lung diseases and allergy in Finland, Estonia and Sweden)  [199] 
and has also been used in Vietnam [200]. Additional questions were added to 
the OLIN-questionnaire, focusing on occupation, airborne occupational and 
environmental exposures, health status and socio-economic status. The 
second part consisted of the Swedish version of the GA2LEN-questionnaire 
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[201, 202]. The two questionnaires complement each other as the OLIN-
questionnaire more thoroughly covers bronchitis and chronic obstructive 
pulmonary disease (COPD), while the GA2LEN-questionniare has detailed 
questions on rhinitis, chronic rhinosinusitis and eczema. The questionnaire is 
included in Swedish as Appendix I. The questions on asthma were similar or 
identical [110]. From the questionnaire the definition of multi-symptom 
asthma (MSA) was created. This definition includes subjects who report 
physician-diagnosed asthma and asthma medication and attacks of shortness 
of breath and recurrent wheeze and at least one additional respiratory 
symptom. 
3.3.1 Study of prevalence trend 
In paper I, the prevalence of asthma and respiratory symptom was studied. 
The questions included in the questionnaire allowed for comparisons with 
two studies performed within the study area in the 1990s. The comparisons 
were performed to determine if there has been a change in prevalence of 
asthma and respiratory symptoms in Gothenburg from the early 1990s to 
2008. Only questions that were similar between the questionnaires were used. 
In the first comparison, the Gothenburg part of the ECRHS survey performed 
on the island of Hisingen in 1990 [34] was used. In this comparison, only 
subjects from the current study matching the study population from 1990 
were used so the comparison only included subjects 20-44 years of age and 
living on the island of Hisingen. The second comparison was performed 
against a study conducted in the county of Södra Älvsborg in 1994 [43]. In 
this comparison, only subjects aged 16-50 years of age and living in Södra 
Älvsborg were included. Södra Älvsborg is included in the county of Västra 
Götaland since 1998. 
 
3.3.2 Study of non-response 
A non-response study should always be performed as a part of 
epidemiological surveys and hence, a non-response study was performed 
during the summer of 2008 [203]. The non-response study is not part of this 
thesis but is vital for the validity of the results and therefore, described 
briefly. From the non-responders that could be identified, a random sample of 
400 was selected. Phone numbers were acquired from two publicly available 
phone records, with phone numbers for 72.2% of the subjects being 
identified. However, 13.8% did not respond to any of the five phone calls that 
were conducted before a subject was considered unreachable. The study was 
a structured interview conducted by a single interviewer containing selected 
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questions from the original postal questionnaire and additional questions on 
reasons for non-response. Of the contacted 234 subjects, 90.2% agreed to 
participate. 
 
3.4 Clinical examinations 
3.4.1 Structured interview 
The extensive structured interviews were conducted by trained nurses and 
contained questions on airway symptoms and diseases, rhinitis and allergies, 
detailed questions on many potential risk factors, utilization of health care 
due to respiratory symptoms and questions on comorbid diseases. The 
Swedish version of the questionnaire is included as Appendix II. In addition, 
separate questionnaires were included for subjects with asthma or COPD. Of 
particular interest for this thesis was the questionnaire on the use of asthma 
medication. This questionnaire contained questions about which type of 
medication the asthmatic had used during the previous year, including short 
(SABA) and long (LABA) acting beta antagonists, inhaled (ICS) and oral 
glucocorticosteroids, combination therapies, anti-cholinergic medication etc., 
with examples of brand names given. The subjects were also asked how often 
they used the medication (never, occasionally, most days) and in the case of 
steroids, how much medication they used per day. Doses were converted to 
beclomethasone dipropionate (BPD) equipotent doses. The Swedish version 
of the questionnaire is included as Appendix III. 
 
3.4.2 Skin prick test  
Atopy to airborne allergens were tested using a standardized panel of 11 
allergens Dermatophagoides pteronyssinus, Dermatophagoides farinae, 
Alternaria alternate, Cladosporium herbarium, Blatella germanica, dog, cat, 
horse, timothy, mugwort and birch (ALK, Hørsholm, Denmark). Histamine 
(10 mg/ml) was used as a positive control, while glycerol was used as a 
negative control. The allergens were applied using a lancet on the forearm 
using standardized methods, however, the allergens was only applied to one 
arm [204]. A mean wheal diameter equal or larger than 3 mm, measured after 
15 minutes, was considered positive. Subjects were asked to refrain from 
anti-histamines for at least 72 hours prior to the visit. 
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3.4.3 Lung function, reversibility and 
methacholine test  
Lung function tests were performed using a Masterscope Spirometer (Jaeger, 
Höcjberg, Germany). The tests were performed with the subject seated and 
using a nose clip. FEV1% predicted was calculated using the ECCS reference 
equation [205]. Subjects were asked to refrain from long-acting broncho-
dilators for 24 hours and short-acting bronchodilators for eight hours prior to 
the visit. 
Reactivity to methacholine was determined using the Spira equipment (Spira 
Respiratory Care Center Ltd, Hämeenlinna, Finland) following a shortened 
protocol. The highest cumulative dose was 1.96 mg. The cumulative dose 
where a 20% decrease in FEV1 was reached was calculated using the 
following formula: PD20 = A+((20-B)*(C-A))/(D-B), where A = 
administered dose methacholine prior to 20% decrease in FEV1, B = % 
decrease in FEV1 after A, C = administered dose methacholine causing a 
minimum of 20% decrease in FEV1 and D = %   decrease in FEV1 after C. 
Reversibility was tested at the same visit to the clinic as the methacholine 
challenge, meaning that some subjects performed the reversibility test 
without a prior methacholine challenge and some performed it after a 
methacholine challenge. As a consequence, not all subjects have been 
reversibility tested in an optimal way. In cases where the subject first 
underwent a methacholine challenge, the subjects were given 4x0.1 mg of 
salbutamol (Ventoline®) followed by two capsules of 4 µg ipratropium 
bromide (Atrovent®) with the reversibility spirometry measured 30 minutes 
after. A spacer was used for both drugs. In cases where no methacholine was 
given, the subject was administered 4x0.1 mg of Ventoline and spirometry 
was performed after 15 minutes. 
 
3.4.4 Exhaled nitric oxide 
Fraction of exhaled nitric oxide (FeNO) was measured using a NIOX 
(Aerocrine AB, Solna, Sweden) at three flow rates; 50, 100, and 270 ml/s. 
This was performed to identify inflammation in different parts of the lung. In 
this thesis, only the value from the 50 ml/s measurement is used. The subject 
performed two exhalations per flow and the average was recorded. 
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3.4.5 Nasal lavage fluid 
NLF was collected from all patients who gave their consent. With the head 
tilted back 30 degrees and the pharynx closed, 5 ml of 10% saline was 
instilled into the left nostril using a plastic syringe. Immediately after 
insertion the head was tilted forward and the fluid passively collected. The 
NLF samples were centrifuged at 300 x g for 10 minutes at 4°C to remove 
cells and stored in -80°C. 
 
3.5 Proteomics 
3.5.1 Study population 
Subjects in paper IV were selected based on characteristics identified in the 
structured interview and clinical examinations. They were stratified into four 
groups; multi-symptom asthma (MSA), multi-symptom asthma with chronic 
rhinosinusitis (CRS-MSA), aspirin induced asthma (AIA) and healthy 
controls. 
Subjects considered to have MSA (please, see Definitions below) in the 
proteomics study had to fulfill the criteria from the postal questionnaire, as 
well as those in the structured interview. They also had to be methacholine 
reactive, or if no methacholine test was performed, have a reversibility of 
more than 12%. If neither was performed, the FEV1% predicted had to be less 
than 90%.  
The selection of CRS subjects was based on answers from the postal 
questionnaire. Subjects classified as CRS-MSA had to fulfill the EP3OS-
criteria, where chronic rhinosinusitis is characterized by two or more 
symptoms (please, see Definitions below) [206]. 
Subjects with AIA reported physician-diagnosed asthma and breathing 
difficulties within three hours of using aspirin or a NSAID. Most subjects in 
the AIA group also fulfilled the criteria for MSA. The report of breathing 
problems after aspirin intake was confirmed via a phone call by a physician, 
where the subjects were asked to describe the event(s) and the severity of the 
reaction. 
Healthy controls reported no respiratory symptoms, physician-diagnosed 
asthma, use of asthma medication or allergic rhinitis and they had a negative 
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skin prick test and methacholine test. Furthermore, they were chosen to 
match the other groups regarding age and gender.  In all groups, subjects 
were excluded if they reported ever smoking, chronic obstructive pulmonary 
disease, chronic bronchitis, emphysema, heart disease, claudicates 
intermittens, stroke, transient ischemic attack, elevated blood fats, diabetes 
mellitus, rheumatic disease or other diseases with a systemic inflammation, 
or had a FEV1% predicted of less than 50%.  
3.5.2 Study design 
The experiment was run in nine different sets, with one sample per group in 
each set, the samples were randomly assigned to a set. To enable quantitative 
comparisons between sets, samples were diluted so that all samples had the 
same protein concentration and a pool containing small amount from each 
sample was created and included in all sets. This pool was always ran with 
the TMT-127 Da tag. As each TMT set can be run using six labels and one 
was always allotted to the pool, five labels were available for samples. The 
samples were randomly assigned one of the five labels, and in each set one 
label was not used. After the samples and pool had been labeled, the samples 
within each set were pooled and fractionation by chromatography was 
performed. Based on protein content, fractions that were to be subjected to 
MS were chosen, Due to low protein content some fractions were pooled two 
and two. On overview of the study design is shown in Figure 4. After MS 
analysis, all sample intensities in a set was compared to the intensity for the 
corresponding peptide in the pool and a ratio was created. In this fashion all 
peptides were normalized, thus enabling comparison between sets.  
 
Figure 4. Study design of the proteomics experiment 
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3.6 Definitions 
3.6.1 Outcomes 
Ever asthma: “Have you ever had asthma”. 
Physician-diagnosed asthma: “Have you been diagnosed as having asthma 
by a doctor”. 
Active (or current) asthma: Ever asthma or physician-diagnosed asthma and 
at least one of use of asthma medication, attacks of shortness of breath, any 
wheeze and recurrent wheeze. 
Multi-symptom asthma: Physician-diagnosed asthma and asthma medication 
and attacks of shortness of breath and recurrent wheeze and at least one 
symptom out of dyspnoea, breathlessness (exercise), breathlessness (cold) 
and breathlessness (exercise in cold). 
Asthmatic (in the clinical follow-up): Physician-diagnosed asthma or ever 
asthma and, in the latter case, either asthma medication, any wheeze or 
attacks of shortness of breath during the last year. 
Asthma medication: “Do you currently use asthma medicine (permanently or 
as needed)”. 
Attacks of shortness of breath: “Do you presently have, or have you had in 
the last 10 years, asthma symptoms (intermittent breathlessness or attacks of 
shortness of breath; the symptoms may exist simultaneously with or without 
cough or wheezing)” and “Have you had these symptoms within the last 
year”. Only the latter, i.e. symptoms within the last year, has been included in 
the analyses. 
Recurrent wheeze:  “Do you usually have wheezing or whistling in your 
chest when breathing”. 
Any wheeze:  “Have you had whistling or wheezing in the chest at any 
occasion during the last 12 months”. 
Wheeze with breathlessness: “Have you had whistling or wheezing in the 
chest at any occasion during the last 12 months” and “Have you been at all 
breathless when you had wheezing or whistling in the chest”. 
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Wheeze apart from cold: “Have you had whistling or wheezing in the chest at 
any occasion during the last 12 months” and “Have you had this wheezing or 
whistling in your chest when you have not had a cold”. 
Wheezing with breathlessness apart from cold: Any wheeze and Wheeze with 
breathlessness and Wheeze apart from cold. 
Dyspnoea: “Do you get breathless when you walk on level ground with 
people of your own age”. 
Breathlessness – exercise: “Do you usually have breathlessness, wheeze or 
severe cough when you exercise”. 
Breathlessness – cold: “Do you usually have breathlessness, wheeze or 
severe cough in cold weather”. 
Breathlessness – exercise in cold: “Do you usually have breathlessness, 
wheeze or severe cough when you exercise in cold weather”. 
Breathlessness – dust: “Do you usually have breathlessness, wheeze or 
severe cough in dusty environments”. 
Breathlessness – strong smell: “Do you usually have breathlessness, wheeze 
or severe cough from strong smells”. 
Difficult breathing after use of pain-killer: “Have you ever had any difficulty 
with your breathing within 3 hours after taking a pain killer”. 
Chronic bronchitis ever: “Have you ever had chronic bronchitis, COPD or 
emphysema”. 
Longstanding cough: “Have you had longstanding cough during the last 
year”.   
Sputum production: “Do you usually have phlegm when coughing or do you 
have phlegm in the chest which is difficult to bring up”. 
Chronic productive cough: Sputum production for at least 3 months during 
two subsequent years. 
Chronic rhinitis: Yes to “Do you have a blocked nose more or less 
constantly” and/or “Do you have a runny nose more or less constantly”. 
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Allergic rhinitis: “Have you now, or have you ever had, allergic rhinitis (hay-
fever) or allergic eye catarrh”.        
Chronic rhinosinusitis: Two or more nasal symptoms, one of which should 
be either nasal blockage or nasal discharge, being present for more than 12 
weeks during the last 12 months. The other two symptoms are facial 
pain/pressure and reduction or loss of smell.                                                                                                                                                                          
 
3.6.2 Risk factors 
Occupational exposure to gas, dust or fumes: “Have you been heavily 
exposed to gas, dust or fumes at work”. 
Smokers reported smoking during the year preceding the survey. 
Ex-smokers reported having quit smoking at least 12 months preceding the 
survey. 
Ever smoker were either smokers or ex-smokers. 
Non-smokers reported neither smoking nor ex-smoking. 
Age at onset: response to “How old were you when you developed asthma”. 
Area of residence was categorized according to population density and 
location. Metropolitan Gothenburg with more than 500 000 inhabitants and 
towns/villages in West Gothia according to size: towns with more than 
10 000 inhabitants, towns with 2 000 - 10 000 inhabitants, villages with 500 – 
2 000 inhabitants and villages and rural areas with less than 500 inhabitants. 
Family history of asthma: “Do any of your parents or sibling have, or have 
had, asthma?” 
Family history of allergy: “Do any of your parents or sibling have, or have 
had, allergic rhinitis or allergic eye catarrh”  
Rural childhood: “Did you live in country-side (i.e. not town or suburb) 
during your first five years of life” 
Farm childhood: “Did your family live on a farm during your first five years 
of life”  
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3.7 Analyses and statistical methods 
3.7.1 Epidemiology 
For all epidemiological original papers in this thesis, the author managed the 
database and conducted all analyses. Quality control of data computerization 
was done by entering 10% of the data from the postal survey twice; errors 
amounted to 0.1-0.2%. Data obtained during the structured interview the data 
was entered directly into the computers. The clinical data has been checked 
for logical errors. Missing data from the postal questionnaire was handled as 
follows: For calculations of prevalence of symptoms and diseases a missing 
answer was considered as a negative answer. For independent variables 
included in risk analyses, all missing answers was coded as missing and 
included in the analyses. All statistical analyses were performed using SPSS 
version 16.0-18.0 (IBM, Somers, NY, USA). In comparisons of prevalence, 
the two-sided χ2-test were used, reported p-values are two-sided Fisher’s 
exact test where a p-value less than 0.05 was considered as statistically 
significant. An unpaired, two-tailed Student’s t-test was used to compare 
means. A Mantel-Haenszel test-for-trend was used when appropriate. 
Univariate and multivariate risk analyses were performed using logistic 
regression, with results presented as odds ratios (OR) with 95% confidence 
intervals.  In paper II, the attributable fraction (AF), i.e. the proportion of 
cases caused by a specific factor, was calculated according to the formula 
((RR-1)/RR)*p, where RR is the Risk Ratio and p is the proportion of 
exposed cases [77]. RR was calculated according to the formula 
(a/(a+b))/(c/(c+d)) where a is the number of subjects with MSA exposed to 
the factor, b is the number of subjects without asthma exposed to the factor, c 
is the number of subjects with MSA not exposed to the factor and d is the 
number of subjects without asthma not exposed to the factor. 
3.7.2 Proteomics 
To be considered for further analyses, a protein had to have been quantified 
in at least three samples in each group. As the expression of most proteins 
followed a normal distribution, the mean ratio of each quantified protein in 
the sample against the same protein quantified in the pool was calculated. 
The fold change (FC) was calculated for each of the asthma groups compared 
to the healthy group. The Student’s t-test was used to determine differences 
in protein expression between the groups. A p-value of <0.05 was considered 
statistically significant. In IPA, molecules that met a 1.3 FC were considered 
and a Benjamini-Hochberg multiple testing correction was applied.  
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4 RESULTS 
4.1 Part 1: Questionnaire survey (Paper I)  
4.1.1 Participation and demographics  
The response rate was higher among women than among men (67% vs. 56%, 
p<0.001) and among subjects living outside the metropolitan area of 
Gothenburg compared to those living in the city (64% vs. 60% respectively, 
p<0.001). Participation increased significantly by age (p<0.001), from 51% 
among those aged 16-25 years to 77% among the oldest aged 66-75 years.  
 
4.1.2 Prevalence of respiratory symptoms and 
asthma  
The prevalence of asthma varied depending on the definition examined. Most 
common was ever asthma, which was reported by 9.7% of subjects. The 
prevalence of physician-diagnosed asthma was 8.3%. Not everyone who 
reported physician-diagnosed asthma reported ever asthma, so when the two 
were combined, the prevalence was 10.2%. The prevalence of subjects with 
physician-diagnosed asthma currently having symptoms was 6.9%. The 
prevalence of ever asthma was highest in the 26-36 year age group at 10.2% 
and then decreased with age.  
Use of asthma medication was reported by 8.6% of the population. Of those 
reporting physician-diagnosed asthma, 70% reported using asthma 
medication, which increased to 84% among physician diagnosed asthmatics 
reporting symptoms. Of subjects with physician-diagnosed asthma and 
reporting at least three of the symptoms that were included in the definition 
of multi-symptom asthma (MSA), 88% used medication. This shows a clear 
relationship between the degree of symptoms and the use of asthma 
medication.  
Respiratory symptoms were common in the study population, with more than 
one-third of the population reporting at least one respiratory symptom. The 
most common respiratory symptom was any wheeze (16.6%), followed by 
sputum production (13.3%), longstanding cough (11.4%) and attacks of 
shortness of breath (9.5%). Forty-six percent of the 5.9% reporting wheezing 
with breathlessness apart from cold had not reported they had ever asthma or 
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physician-diagnosed asthma, a result corresponding to 2.7% of the 
participating study sample.     
Gender aspects 
In general, the prevalence of asthma was higher among women than among 
men: ever asthma 10.5% and 8.7% respectively (p<0.001) and physician-
diagnosed asthma 9.1% and 7.4% (p<0.001). In addition, most symptoms 
common in asthma were significantly more prevalent among women, while 
bronchitic symptoms were equally common in men and women. The use of 
asthma medicines was reported by 6.8% of men and 10.1% of women 
(p<0.001).  
Prevalence trends 
Compared with studies performed on the island of Hisingen, Gothenburg, in 
1990 [34] and a study performed in the county of Södra Älvsborg in 1994 
[43], a decrease in the prevalence of most respiratory symptoms was 
observed, while there were increases in the prevalence of asthma and use of 
asthma medication. Notably, there was a large decrease in smoking during 
the period from 32% in 1990 to 18% in 2008, when subjects in the same ages 
are compared. 
 
4.1.3 Risk factors  
Current smoking was a strong risk factor for all investigated symptoms, with 
ORs ranging from 1.81-3.88. Additionally, ex-smoking was a risk factor for 
respiratory symptoms and for physician-diagnosed asthma, but the effect was 
not as strong. Allergic rhinitis and a family history of asthma were strong risk 
factors, especially for physician-diagnosed asthma and attacks of shortness of 
breath. Neither gender nor regions of domicile were strongly associated with 
any of the respiratory symptoms or with asthma. Occupational exposure to 
gas, dust or fumes was significantly associated with all investigated 
symptoms and with asthma. The strongest associations were found for 
recurrent wheeze (OR 2.2) and attacks of shortness of breath (OR 1.8) 
(Figure 5). 
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Figure 5. Occupational exposure to gas, dust or fumes as a risk factor for physician-
diagnosed asthma and respiratory symptoms. Abbreviations used in the figure: PhD- 
physician diagnosed, SOB-shortness of breath, Rec. – recurrent, prod. - production 
4.2 Part 2: Questionnaire survey and 
clinical examination (Paper II and III)   
4.2.1  Prevalence of multi-symptom asthma 
Multi-symptom asthma was detected in 2.0% of the population; comprising 
24% of the subjects with physician-diagnosed asthma and more common 
among women. Unlike asthma as a whole, no significant differences were 
found by age. The prevalence among other asthma for the symptoms that 
were required to be included in the MSA group was 59% (asthma 
medication), 51% (attacks of shortness of breath) and 15% (recurrent 
wheeze). All investigated respiratory symptoms were more common among 
MSA compared to other asthma except allergic rhinitis which was equally 
common at 65% (Figure 6). 
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Figure 6. Prevalence of symptoms among subjects with multi-symptom asthma and 
other asthma. 
Figure 7. Asthma control according to GINA in multi-symptom asthma and other 
asthma. 
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4.2.2 Validating the questionnaire definition 
using clinical variables 
Lung function, expressed as FEV1% of predicted, was lower among MSA 
than in other asthma (89% vs. 99%) and MSA displayed more hyper-
reactivity to methacholine, with 83% having a PD20 less than 1.96 mg 
compared to 59% among other asthma. The methacholine challenge had a 
sensitivity of 82.5 and a specificity of 60%. The airway inflammation, as 
measured by exhaled NO, was higher in the MSA group, and morbidity 
variables, particularly emergency unit visits, asthma exacerbations and night-
time awakening, were considerably more common among MSA compared to 
other asthma. According to the GINA 2006 classification, 59.4% of subjects 
with MSA had uncontrolled or poorly controlled asthma compared with 
28.2% among subjects with other asthma (Figure 7). 
 
4.2.3 Differences in use of asthma medication 
Of the whole asthmatic population, 65% were using asthma medication at the 
time of clinical examinations. The prevalence of medication use for asthma 
was 92% among MSA and 58% among other asthma. Almost twice as many 
subjects with MSA used ICS compared with other asthma (71% vs. 40%, 
p<0.001). About half of the subjects using ICS also used LABA, with a 
majority using a combination inhaler. Among subjects not using steroids, the 
prevalence of SABA use was 70% in the MSA group and 28% in the OA 
group (p<0.001). With increasing age, all groups reported an increased 
prevalence in the use of ICS and combination treatment. In general, the 
prevalence of medication use was higher among women.  
One-third of the subjects with asthma used ICS daily, or on most days. More 
than half of the subjects with MSA used ICS most days, but only one-fourth 
of the subjects with other asthma used ICS to the same extent. Thirty seven 
percent of subjects with multi-symptom asthma used a combination treatment 
most days, compared with 15% of the subjects with other asthma. Oral 
steroids and bronchodilators through a nebulizer were predominantly used 
periodically or occasionally. 
Most asthmatic subjects were using a medium dose of ICS, with only 3% of 
asthmatics using a high dose of more than 1000 µg BPD, or equipotent dose 
of other ICS, daily. Using a high dose of ICS was more common in the multi-
symptom asthma group (8%), compared to the other asthma group, where 
only 2% used a high dose. 
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4.2.4 Risk factors  
Having a family history of both asthma and allergy was the strongest risk 
factor for MSA compared with non-asthma, with an OR of 7.3, while the OR 
for having a family history of either asthma or allergy were approximately 
2.7. Other significant risk factors included occupational exposure to gas, dust 
or fumes (OR 2.0), female gender (OR 1.6), age 61-75 (OR 1.5) and current 
smoking (OR 1.3). 
When other asthma was used as a reference, older age became a stronger risk 
factor, while having a family history of asthma or allergy had decreased 
importance. Older age was a “protective” factor for other asthma, in contrast 
to MSA, where older age was a risk factor. 
The attributable fraction of several independent factors on MSA was 
calculated. Having a family history of allergy explained 37%, a family 
history of asthma explained 33% and occupational exposure to gas, dust or 
fumes explained 17% of the MSA in the study population. In a stratified 
calculation, occupational exposure to gas, dust or fumes was found to be a 
much stronger attributable factor for MSA among men (AF 35%) than for 
women (AF 13%).  
Mainly as a result of the definition of MSA, having MSA was a considerably 
stronger risk factor for asthma medication use than having other asthma in 
adjusted logistic regression models. There were few other significant risk 
factors for medication use, with increasing age and living in a town of 2 000-
10 000 inhabitants reaching significance.  
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4.3 Part 3: Proteomics of asthma 
phenotypes 
4.3.1 Demographics 
There was more airway inflammation, measured as FeNO, in the CRS-MSA 
group compared to AIA, MSA and healthy. No differences in FEV1/FVC 
ratio, blood neutrophils, blood eosinophils, or in differential cell count of 
cytospins of the NLF, between the groups were found. There were slightly 
more women in the group with AIA. 
4.3.2 Protein analysis 
In total, 790 proteins were identified, with 721 also quantified. Of the 721 
proteins, 474 proteins had been quantified in at least three subjects per group 
and were included in the functional analysis. In IPA, a FC of 1.3 was applied 
as a cut-off and 193 proteins had a FC of more than 1.3 compared to healthy. 
Of these 193 proteins, 50 were unique to AIA, 39 to CRS and 31 to MSA. 
The remaining 73 proteins were common to two or all asthma groups. 
GO Term Finder identified the 73 proteins that were common between 
groups to be enriched in immune defense processes such as defense response, 
response to stress, complement activation, innate immune response and 
response to stimulus. Decreased expression of specific proteins suggests 
impaired protective defenses, increased defense response and response to 
stress.  
In proteins uniquely altered in AIA, the enriched biological processes 
included regulation of catalytic activity, specifically endopeptidase activity, 
while proteins unique to CRS were enriched in response to stress and 
epithelial cell differentiation. Proteins unique to MSA were enriched in 
biological processes of negative regulation of molecular function, immune 
response and defense response.  
The 73 proteins common to all three groups of asthma had a more even 
distribution (percent hits against total number of proteins in the dataset) over 
the PANTHER protein classes, than the proteins that were unique to the 
different asthma groups. In general, all groups had protein classes involved in 
active metabolic and immune system processes, response to stimulus and few 
protein classes involved in apoptosis. The unique proteins of subjects with 
CRS-MSA had an overrepresentation of processes involved in structural 
changes, in contrast with AIA and MSA, 
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which had very little structural activity. The molecular function of transporter 
activity was common in AIA, but was rare in MSA and CRS-MSA.  
IPA identified the biological category of “Respiratory Disease” to be 
associated with all groups. The top categories in all groups were 
“Dermatological Conditions and Diseases”, “Immunological Disease” and 
“Inflammatory Disease. “Asthma” was among the top five associated 
biological functions for MSA. “Hypersensitive Reaction” was strongly 
associated to AIA and MSA. For all three groups, the main associated 
biological functions were involved with skin diseases such as dermatitis, 
psoriasis and atopic dermatitis. IPA identified several significantly associated 
networks for each of the asthma phenotypes. Proteins previously found to be 
involved in asthma, CRS and the COX pathway were present in the top 
networks.  
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5 DISCUSSION 
5.1 Discussion of methodology 
5.1.1 Validity  
The validity of a study is its ability to measure what it is suppose to measure. 
The internal validity is how well results from the study population represent 
the population the sample was drawn from. The external validity is how well 
results from a study can be applied to other populations.  
The representativeness of the study population is crucial for the validity of a 
study. This study was a cross-sectional study performed on a representative 
sample of the population in Västra Götaland, selected in a stratified manner. 
Different response rates in the different age groups and between genders 
might influence the results; therefore a non-response study was performed to 
investigate the internal validity of the questionnaire survey. This non-
response study indicated no differences in regards to the prevalence of 
respiratory symptoms between responders and non-responders. However, the 
non-responders were more often male, young, smokers and living in 
Gothenburg. This implies that the prevalences reported here can be 
extrapolated to the population of Västra Götaland. However, the importance 
of young age and smoking as risk factors might have been underestimated, 
although the study gave no such implications [203]. Some caution must be 
taken when the results from the non-response study are analyzed as it was 
performed among a randomly selected sample were 53% participated. 
Participation in the clinical survey was 59% in the random sample and 55 % 
among asthmatics. All of these subjects are not included in the papers 
included in this thesis and it is difficult to evaluate the representativeness of 
the subjects. The participants in the clinical examinations are more likely to 
be females and of older age, much like the responders to the postal 
questionnaire. It is also clear that asthmatics are slightly overrepresented 
among the participants in the clinical survey, as 9.6% were identified as 
asthmatics in the postal questionnaire, but made up 11.3% of the participants 
from the random sample in the clinical examinations. A comparison of 
responses to the postal questionnaire for participants and non-participants in 
the clinical survey has not been performed yet. However, the data from the 
clinical follow-up has not been used to estimate prevalence in the entire 
population, but only within a group and hence the somewhat skewed 
participation should not play a major influence on the results. 
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 The large sample size and the use of well validated questionnaires contribute 
to the high internal validity of the results. The questionnaires used in the 
study have been used in various studies, and the questions on physician 
diagnosed asthma and respiratory symptoms have been evaluated [107, 207]. 
The use of the two questionnaires also allows for more precise comparisons 
with other studies, as questions from the OLIN-questionnaire can be used 
when comparisons are made with studies in Northern Europe that have used 
the OLIN-questionnaire, and the GA2LEN-questionnaire can be used in 
comparisons to other centers within the GA2LEN network and ECRHS. The 
estimates of prevalence reported here are similar to recent reports from other 
parts of Sweden and Northern Europe [33, 39, 199] suggesting a high 
external validity of the questionnaires used in this study. 
5.1.2 Bias 
Bias is a systematical error that might occur in a dataset, there are many 
different forms of bias, some of which will be discussed here. 
Selection bias 
Once a study question has been formulated and study subjects identified, it is 
important that these subjects be recruited uniformly and that data about the 
health and exposure be collected consistently. If certain subjects are not 
enrolled in the study, or if information is collected differently for different 
subjects, the resulting bias could invalidate the study. Selection bias can 
occur when not everyone eligible to be in a study can be selected as a subject, 
and when those selected are different from those excluded, in a systematic 
way. To avoid selection bias, comparison populations must be selected that 
are similar, except for the specific factors under study, and that is often 
difficult to achieve. This study was a random population study but certain 
parts of the population may be hard to reach, or choose not to answer. As the 
non-response study shows, it is unlikely that this has impacted on the 
outcomes in a major way.  
Recall bias 
Sometimes the subjects' ability to recall and report past experiences may be 
affected by their preconceived ideas about a possible health hazard, such as 
exposures in the work environment. This is hard to control for in cross-
sectional studies, but by asking for symptoms and exposures during the last 
year recall bias can be reduced. The variables used in the definition of MSA 
have slightly different time spans as part of their definitions, this might cause 
symptoms being anterior to asthma medication, which might influence recall. 
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5.1.3 Confounding 
Confounding is when an association is found for the incorrect reason and is a 
common and important factor to take into consideration. It is associated with 
both the risk factor and the disease being studied, but does not need to be a 
risk factor for the disease under study. The confounding variable can either 
inflate or deflate the true association. To investigate the true association one 
has to investigate all factors thought to cause confounding at the same time. 
Several variables may be confounders in any study, the effects may be small 
or large but failure to account of the most important confounders may lead to 
the validity being questioned. It is not possible to account for all potential 
confounders as there are so many of them.  
 
5.1.4 Misclassification 
Misclassification is a technical term for mislabeling or mischaracterizing a 
study subject, and may occur with diseases or exposures. For example, older 
subjects, particularly those who smoke, might prefer to have asthma to 
having COPD. Subjects who only smoke occasionally, or a couple of times a 
year might not regard themselves as smokers. When we defined MSA, we did 
not intend to define severe asthma, but to find an epidemiological marker of 
severe disease. Our definition is not able to distinguish between, for instance, 
subjects with a persistent severe asthma and subjects with brittle asthma and 
lack of adherence to treatment. It may be that subjects identified using the 
current method could be more sensitive to symptoms, rather than having a 
more severe disease. It might even be argued that some subjects with MSA 
may have some features of COPD, however, this is contradicted by the mean 
age of onset of asthma at 25 years and the presence of only nine smokers 
above the age of 50 having a FEV1/FVC ratio <0.7. There might also be a 
misclassification in regards to medication use. The main weakness in this 
regard, is the lack of objective measurements of medication use, such as 
blood levels of pharmaceutical metabolites. In the proteomics study, two 
subjects included in the AIA groups had CRS, so these subjects were 
excluded to reduce complexity and keep the groups as pure as possible. A 
limitation in the inclusion of subjects in the proteomics study was the absence 
of questions in the structured interview regarding CRS, and as a consequence, 
the inclusion was based on responses to the questionnaire survey. 
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5.1.5 Statistical Variation 
Statistical variation is really chance fluctuations and the risk of the results 
being influenced by statistical variation decreases with increasing sample 
size. The statistical variation is an important factor in power calculations. 
Epidemiological studies are made on samples of a larger population, and 
because of statistical variation, the results will be at least a little different than 
if the entire population was tested. There are several ways statisticians 
estimate the effect of statistical variation and hence the uncertainty of the 
findings: 95% confidence intervals and p-values being two of the most 
common. In the proteomics study, the individual variation at protein level is 
known to be high, and the method itself causes further variation. However, 
multiplexing using the TMT-technique reduces experimental variance and to 
reduce the impact of the individual variation, a minimum of three values per 
group were required with a FC of at least 1.3. To have a power of 0.8, with a 
variation of 40% and a 1.5 FC would require eight samples per group.  
5.1.6 Determinants of disease 
Data of exposures and other determinants of disease were collected using the 
postal questionnaires and no objective measures were used. Missing answers 
for questions on exposures were treated as missing, while missing answers 
were treated as “no” for symptoms and diseases,  in line with the standards of 
interpretation of data after validation of the questionnaire [197]. In this way, 
no over estimation of prevalences or risk is done. The cross-sectional design 
has the weakness of not being able to conclude anything about causality for 
possible determinants which makes discussion of cause or consequence, as 
well as detected associations, more difficult.  
5.1.7 Definitions 
We have used different definitions of asthma to enable comparisons with 
different studies. The definitions for papers I-III was based on questionnaire 
data while clinical data was used in paper II and III. For paper IV, the 
definition of asthma was based on the structured interview and on clinical 
data.  
Defining multi-symptom asthma 
In the late 1980s and early 1990s it was found that recurrent wheeze and 
attacks of shortness of breath, two of the core symptoms of MSA, correlated 
with impaired lung function [208] and hyper-reactivity [209], particularly in 
asthmatics. This was verified in an Estonian study in 1996 [210]. In 2007-
2008 a large population based interview study of subjects with physician-
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diagnosed asthma in Stockholm, Sweden (unpublished data) identified 
certain morbidity variables as considerably more common in those reporting 
the above symptoms. The triggers exercise and cold were selected, because 
they are less biased compared with symptoms caused by irritants such as 
tobacco smoke and dust, which also strongly correlate with sensoric 
hypersensitivity without bronchial obstruction. Further, the large European 
Network For Understanding Mechanisms of Severe Asthma study 
(EMFUMOSA) has shown that triggers connected to allergy, i.e. pollen and 
furry animals, are inappropriate to use in identifying severe asthma.  
 
5.1.8 Choice of proteomics method  
Isoelectric focusing (IEF) and gel electrophoresis (GE), while not used in this 
thesis, are important tools in proteomic research and are briefly described 
here. IEF relies on the fact that the net charge of a protein varies with the 
surrounding pH proteins are separated according to their isoelectric point 
(pI). In two dimension gel electrophoresis (2-DGE), proteins are separated by 
both pI and mass enhance separation and then detected. At this stage, the 
identity of the proteins are unknown additional analysis, for example using 
MS, are required. In theory, 2-DGE can reveal virtually all proteins in a cell 
or tissue at any given time. 2-DGE has the advantage of identifying all 
isoforms of a protein, a feature that is hard to achieve in MS.  
As, 2-DGE MS also has advantages. MS allows for a large proportion of the 
proteins in a sample to be identified and quantified. MS however has the 
limitation that certain proteins are more difficult to ionize, resulting in failure 
to identify to protein. The reason for this feature still remains to be 
elucidated. When quantitative studies are performed some peptides are more 
likely to be labeled, which might cause some bias. However, the TMT-
technique is designed to minimize this problem.  
In ESI, the solvent is evaporated, reducing the size of the droplets until the 
droplet disintegrates and solvent-free gas-phase ions are produced. When the 
amount of sample is limited a low-flow electrospray, nano-ESI [211], is used. 
In nano-ESI the spray needle is very thin and positioned close to the mass 
analyzer. These adjustments result in very small droplets and consequently a 
reduction in the amount of sample needed. ESI allows for direct coupling 
with separation techniques such as nano LC. The Orbitrap have a high 
resolution, a high mass accuracy in the low ppm range, a high mass-to-charge 
range and a dynamic range of more than three orders of magnitude [212, 
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213]. When the Orbitrap is combined with a LTQ, an instrument is created 
that benefit both from the high resolution and mass accuracy of the Orbitrap 
and the speed and the sensitivity of the LTQ. The LTQ Orbitrap Velos MS 
have a rapid quantitation of low level isobaric labeled peptides and is fast 
which is important when complex samples are being analyzed [214]. 
Connecting a nano LC to the mass spectrometer increases the resolution up to 
100 times. The separation and concentration of components results in higher 
sensitivity and efficiency and at the same time salts and other impurities are 
removed. 
Which database that is used for protein identification depends on data source 
and in which species the search is performed. In addition to the database 
several factors will affect the search results. In this thesis MASCOT, a 
software search engine, was used for MS/MS spectra searches where 
experimental MS/MS spectra were compared against theoretical spectra in 
the UniProt Swiss-Prot database. Peptides were identified and fit into 
proteins sequences for protein identification. To reduce false positives, the 
results are also search against a decoy database where the proteins sequences 
are reversed or random, a false discovery rate (FDR) of <1% is usually 
required. Proteome Discoverer (Thermo Fisher Scientific Inc., Waltham; 
MA, USA) is a for database searches to identify proteins which can 
incorporate several database search algorithms and validate proteins with 
FDR determination. The 1.3 FC threshold was chosen based on the 
variability of human samples, which often ranges up to 20%. As most 
proteins, but not all, were found to be normally distributed, Student’s t-tests 
was used identify the significantly different proteins. No correction for 
multiple comparisons was used, as there is currently no consensus on how to 
perform these corrections in proteomic samples. It is important to use as 
many individuals as possible in clinical proteomics as the variation is high 
and peptides are not always quantified which reduces the power. 
MS studies without quantification usually results in a higher number of 
identified proteins, compared with studies where quantification is performed, 
due to the lower complexity of the sample. In our study, the aim was not to 
describe the protein content of different asthmatic groups, but to compare 
them with regards to expression levels and hence a quantitative approach was 
chosen. There are several available quantification techniques. In a pilot-study 
performed in our lab, iTRAQ and TMT labeling techniques were compared 
for NLF. iTRAQ resulted in more quantified proteins but only allows for 
three samples and one pool per set while TMT allows for five samples and 
one pool per set. TMT was chosen as the reduced variability with a reduced 
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number of sets was considered as more important than having more 
quantified proteins. 
A problem with using a database such as the Ingenuity® Knowledge Base is 
that the results are influenced by what has been included in the database. The 
Ingenuity® Knowledge Base, despite being very comprehensive and 
manually reviewed, has an overrepresentation of research on cancer and 
cancerous cell lines, and a protein, although involved in many diseases, may 
have been associated with many types of cancer, resulting in a bias. 
5.1.9 Choice of sample for asthma proteomics  
Studies of respiratory proteomics have identified several biomarkers but there 
has been difficulties verifying the results. This could partly be due to patient 
selection where the syndrome of asthma, rather than specific phenotypes, has 
been studied. Accessing disease relevant samples is a problem when 
proteomic studies of respiratory diseases are being performed, therefore cell 
cultures and animal models have frequently used [215]. Studies on human 
samples have been performed in sputum [216], BLF [183, 186, 217], biopsies 
[218] and exhaled breath condensate [219]. While BLF and bronchoalveolar 
biopsies are taken from the site of disease they are very invasive. Serum is 
easily accessible but is not from site of disease and there are issues with 
abundant serum proteins obscuring expression of less common proteins. 
Sputum is usually easy to induce in symptomatic symptoms but this can be 
difficult in healthy control subjects. It is also unknown how the instilled 
hypertonic saline affects the sample. NLF suffers from problems with 
dilution, as does BLF, but is non-invasive and can be obtained from most 
subjects. While it is not site of disease the upper airways may reflect the 
milieu in the lower airways in line with the united airway concept [220]. 
Studies previously performed on NLF have commonly used 2-DE, followed 
by protein identification of selected spots by MALDI-TOF [183, 187, 221]. 
As these studies only identify selected protein spots, and not all visible on the 
2-DE gel, these studies have identified far less proteins than the current 
study; however Lindhal et al detected approximately 1000 proteins in the 
2DE gel using image analysis [187]. Benson et al identified 197 proteins 
using LC-MS/MS on extensively fractionated pools of NLF containing up to 
2 mg of protein, far less than in the current study [222]. Wang et al identified 
451 proteins using LC-MS/MS, comparable with the current s [171]. 
Differences might be due to differences in the method for collecting NLF, 
different search criteria or different versions of the database being searched.   
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5.2 Discussion of main results 
5.2.1 Paper I-III 
Prevalence of asthma and respiratory symptoms 
The prevalence of physician-diagnosed asthma in this study was estimated to 
be 8.3%, similar to what has been found in other parts of Sweden [93, 199, 
210, 223]. Compared with the results from the ECRHS study in Gothenburg 
in 1990 [34] and the Södra Älvsborg study preformed in 1994 [43], a very 
small increase in asthma prevalence could be observed. It is however unclear 
if the increase is true or a result of changed diagnostic criteria. The small 
increase is in line with studies of asthma incidence that have shown a stable 
incidence of about 2/1000/year since the mid 1980s (Figure 8). Increasing 
asthma prevalence in older age groups has been reported previously, 
however, this was not observed in the current study. Use of asthma 
medication was reported by 8.6%, a prevalence that is in accordance with the 
ECRHS study [141, 224] and with recent studies from the Nordic countries 
[33, 142, 143, 201, 225]. Asthmatics reported less respiratory symptoms and 
only 6.9% had active asthma. Of these subjects, only half reported both use 
of asthma medication and one or two symptoms. The finding suggests that a 
greater proportion of mildly symptomatic asthmatics are being diagnosed as 
having asthma, as those who were diagnosed with asthma in the 1980s and 
1990s had more symptoms of asthma than found in the current study and 
other recent studies (Figure 9) [90, 198].  
A clear decrease in respiratory symptoms compared with the 1990s was 
observed. This was true for both genders and all age groups. Symptoms that 
may be related to smoking, such as any wheeze, sputum production and 
longstanding cough, as well as symptoms closely related to asthma, such as 
wheezing with breathlessness, had decreased. The observed increase of 
allergic rhinitis might reflect an increase in allergic sensitization in the area, 
possibly leading to a future increase of allergic asthma. The reduction in 
symptoms related to smoking is not surprising, as the prevalence of smoking 
had reduced by 44% during the time between the studies.  
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Figure 8. Trend in asthma incidence. Reprinted from Ekerljung et al, Resp Med 
2008, 102:1730 with permission from Elsevier. 
Figure 9. Prevalence of active asthma in Stockholm and Gothenburg with numbers of 
indicators (asthma symptoms or use of asthma medication). Modified from Ekerljung 
et al Int J Tuberc Lung Dis 14(6):764–771 and Lötvall et al Respir Res. 2009 
12;10:94. 
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Multi-symptom asthma as a marker of severe disease 
MSA was present in 2% of population and in one of four asthmatics. Subjects 
who report multiple symptoms, despite use of asthma medication, were more 
likely to suffer from more severe asthma as they have significantly lower 
lung function, express signs of increased airway inflammation, are more 
hyper-responsive, have more night-time awakenings and report more 
symptoms due to environmental triggers, compared to with those with less 
symptoms of asthma. Almost all subjects with MSA still used asthma 
medication one to four years after the postal survey, indicating stability in the 
definition. Despite the use of asthma medication, a large majority of the 
multi-symptom group also had signs of uncontrolled or poorly controlled 
asthma as defined by GINA 2006 [127]. The current study reflects a 
population with signs of more severe disease with a similar gender 
distribution to what was reported in the population based ECHRS study [226] 
and to the patient based EMFUMOSA study [118, 148], with women being 
more frequently affected. The definition is not sufficient to encompass all 
aspects of severe asthma, but many similarities are present.  
 
Medication use 
Of those having asthma according to the postal survey, 8.6% used asthma 
medicines regularly or as needed [142]. The random sample in the clinical 
cohort is not completely representative of the responders to the postal 
questionnaire. In the random sample, 11.4% reported physician-diagnosed 
asthma compared with 8.3% in the postal questionnaire. The prevalence of 
use of asthma medication in the interview was 9.8% when adjusted for the 
higher proportion of asthmatics.  
One to four years after the postal survey, almost all asthmatics with multiple 
symptoms still reported use of asthma medication, which was one of the 
inclusion criteria of MSA in 2008, compared with 63% among asthmatics 
with fewer symptoms. Subjects with MSA used their medication more 
frequently and in higher doses than those classified as having other asthma. 
Further, maintenance treatment was considerably more common among those 
with MSA. In our study, 70% of MSA and 40% of other asthma used 
steroids, comparable with a study by Liou et al [154] and higher than a study 
by Cerveri et al [227]. Suboptimal dosing has been found to be similar 
between severe and mild asthma [154].  
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Our estimation that up to 30% of MSA can be due to low adherence or under-
treatment, is comparable to a study by Gamble et al [155] where 35% of 
asthmatics had non-adherence as the main cause of difficult-to-treat asthma.  
 
Risk factors 
As the study design was cross-sectional, the results only verify an association 
and conclusions on cause or consequence are difficult to make. However, risk 
factors that are stabile over long time periods, such as smoking, family 
history of asthma and, not least, gender, can often mean causality. Female sex 
and ex-smoking were closely associated with asthma, with risk factor patterns 
that were similar to previous studies, [90, 198, 199, 223]. The reduced 
importance of a family history of asthma on the risk of asthma could possibly 
be explained by the inclusion of patients with milder disease in this category 
than previously [90, 198]. This is supported by family history of asthma and 
allergy being the strongest risk factors for MSA. In our study, the prevalence 
of asthma was highest in the age group of 26-35 years, while it was lower in 
the age group of 16-25 years, arguing against a further increase in prevalence 
of asthma in the lower age group. In studies performed in the 1990s, asthma 
was most common in adolescents and young adults [198]. Respiratory 
symptoms were less age-dependent when compared to previous Swedish 
studies [198, 228, 229]. However, chronic respiratory symptoms increased 
with increasing age. Particularly symptom of bronchitis have been strongly 
age and smoking dependant, this trend cannot be seen in the current study, 
probably due to the considerable decrease in smoking and a decrease in 
outdoor air pollution. The lack of difference between the metropolitan area of 
Gothenburg and the non-metropolitan area may also reflect an improvement 
in the outdoor air pollution in the metropolitan areas in Sweden [230] 
Smoking and occupational exposure to gas, dust or fumes had a greater 
impact on MSA compared with other asthma. Occupational exposures and air 
pollutants are known risk factors for asthma [77] and with similar exposures 
at work, severe asthmatics more frequently reported that work affected their 
breathing [231, 232]. When investigating subjects with multiple risk factors, 
we found that the hereditary factors are the most prominent factors related to 
increased risk of MSA. In the absence of a hereditary factor, an increased risk 
at the population level was observed only if both smoking and occupational 
exposure of gas dust or fumes were present. If a hereditary factor was 
present, the concurrent presence of smoking and/or occupational exposure to 
gas, dust or fumes resulted in a ten-fold increased risk of having MSA 
compared with subjects who have none of the risk factors.  
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5.2.2 Paper IV  
The current proteomics study is considered a screening, hypothesis 
generating, survey for future studies. Interesting results must be verified in a 
larger patient sample using complementary methods like ELISA or Western 
blot. It is difficult to draw finite conclusions in regards to potential 
biomarkers but it is clear that a quantitative MS/MS approach on NLF can be 
used to identify differences between the phenotypes in regards to mechanistic 
differences, with different biological functions and pathways associated with 
the phenotypes. Proteins that were common between the phenotypes 
(compared to healthy) include molecules involved in defense response, 
response to stress, innate immune response and coagulation related processes. 
The samples in the CRS-MSA group were more different than the AIA and 
MRS group. This could possibly be due to the site of sampling which, in the 
case of CRS, is also the site of disease. In hindsight it would have been useful 
to have a group with CRS but without asthma to identify features unique to 
CRS. The absence of AIA relevant proteins previously identified could be 
partly explained by those studies using samples obtained during aspirin 
provocation.  There are also proteins that are significantly different between a 
phenotype and the healthy individuals.  The question we have to ask is 
whether the differences identified between the phenotypes are relevant; this 
needs to be studied in further experiments.  
The advantage of using NLF is mainly easy access and relatively non-
invasive sampling procedure. However, the site of sampling is distant from 
the main site of bronchial inflammation, which poses a limitation in detecting 
lower airway disease relevant proteome information. However, both proteins 
common in asthma, and proteins previously associated to the investigated 
phenotypes are present in the samples [174, 184, 186, 233, 234]. 
Additionally, the 2-DE profiles of samples from NLF and BLF have been 
found to be similar [183]. When our data is compared to data from other NLF 
proteomic studies [171, 222, 235, 236], 295 proteins had not previously 
identified. The high number of quantified proteins suggests that the method 
used in this study was quite thorough. The combination of the fractionation, 
with the sensitivity of the LTQ-Orbitrap Velos instrument, resulted in a high 
yield of proteins.  
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6 CONCLUSION 
1. The prevalence of asthma was 8.3%. 
 
2. The previous increase prevalence of asthma has leveled off 
in West Sweden. 
 
3. The prevalence of most respiratory symptoms decreased.  
 
4. The prevalence of multi-symptom asthma was 2% in the 
general population and 24% among asthmatics. 
 
5. The definition of multi-symptom asthma does not define 
severe asthma, however can be used as an epidemiological 
marker of more severe disease.  
 
6. The prevalence of asthma medication use was 8.6%, of 
subject with a physician-diagnosed asthma, 70% used 
asthma medication. 
 
7. Subjects with multi-symptom asthma used more asthma 
medication and in higher doses compared with subjects with 
other asthma. 
 
8. Multi-symptom asthma is only partly due to non-use of 
medication.  
 
9. Differences in functions, pathways and protein expression of 
phenotypes of asthma compared to healthy can be detected 
using MS/MS in NLF.  
 
10. Proteins detected in NLF reflect, at least in part, the milieu 
in the lower airways. 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
52 
ACKNOWLEDGEMENTS 
I wish to express my sincere gratitude to all my colleagues, friends and 
family for all you support during my work with this thesis. My special thanks 
go to: 
All the participants in the West Sweden Asthma Study, especially all 
those that spent 3 (or more) hours at the clinic. This study would not be what 
it is without you.  
My supervisor, Bo Lundbäck, who introduced me to the field of respiratory 
research and whose enthusiasm and knowledge of the field is extraordinary. 
Thank you for inviting me to Gothenburg and letting me be a part of the 
WSAS-study and for your belief in, and patience with, me even though we 
did not always agree on how things should be done.  
My co supervisors, Margareta Sjöstrand and Jan Lötvall, for welcoming 
me to Gothenburg and the lab, for your support and advice. 
My mentor, Eva Rönmark, for always believing and supporting me. Thank 
you for letting me be a part of the OLIN-family at congresses and meetings.   
My roommate at work, Serena, for your friendship and endless proof reading 
and language revisions, not least of this thesis. For introducing me to IPA, 
discussing the proteomics with me and helping me to put the paper together.  
My co PhD-students at KRC, Maria and Cecilia, for your friendship, many 
laughs and discussions, shared pains and nice travel companionships. For 
keeping my company in the general pre-dissertation stress and for helping me 
put things in proportions.  
The department secretary, Eva-Marie, who always had the answers when I 
got lost in the administrative system.  
All the other colleagues at Krefting Research Centre for the nice camaraderie 
and many “pek-fikas”. A special thanks to Anders for helping me see the 
future ahead and many fruitful science discussions. 
The staff at the proteomics core facility, Sara and Carina, for helping me 
with the proteomics. For patiently explaining the methods to me and 
performing the experiments.  
Linda Ekerljung 
 
 
53 
The nurses at Krefting Research Centre who performed the clinical part of 
West Sweden Asthma Study. 
My oldest and best friend in the whole world, Linnea, for a life-long 
friendship, for all the laughs, pains and experiences we have shared. A 
special thanks for helping me get access to hard-to-find papers. Who would 
have thought that we would end up doing research in similar fields?  
My dear friend Hanna and her husband Thomas who have always had room 
for me when I needed it, always made me feel more than welcome and 
helping me see things for what they are.  
My friends from university, Maria and Evelin. For all our study sessions, 
baking of “lussekatter” and “semlor” and many great dinners. I wouldn’t 
have gotten through first year without you. 
The world’s best dog sitter, Ulla, who have taken such good care of my 
darlings while I have worked on this thesis.  
My brother Magnus, and his family Jenny and William, for all the support 
and encouragement, for nice travels, many games and shared love of 
whiskey. 
My parents, Sussi and Lasse for being the best parents I could ask for. For 
supporting me and believing in me, making sure I knew I could be anything I 
wanted. My grandma Ann-Britt who always made me feel loved and special, 
who have knitted me endless warm sweaters over the years which have 
prevented me to freeze in cold offices. A special thought also goes to my 
grandmother Bian, my grandfather Ingemar and my grandpa Sten, who are 
no longer with us. You will always be remembered.  
 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
54 
REFERENCES 
1.Cochrane AL, Chapman PJ, Oldham PD. Observers' errors in taking 
medical histories. Lancet. 1951 May 5;1(6662):1007-9. 
2.Fairbairn AS, Wood CH, Fletcher CM. Variability in answers to a 
questionnaire on respiratory symptoms. Br J Prev Soc Med. 1959 
Oct;13:175-93. 
3.Fletcher CM, Elmes PC, Fairbairn AS, et al. The significance of 
respiratory symptoms and the diagnosis of chronic bronchitis in a 
working population. Br Med J. 1959 Aug 29;2(5147):257-66. 
4.Higgins IT, Cochrane AL, Gilson JC, et al. Population studies of 
chronic respiratory disease. A comparison of miners, foundryworkers, 
and others in Staveley. Derbyshire. Br J Ind Med. 1959 Oct;16:255-68. 
5.Medical Research Council's Committee on the aetiology of chronic 
bronchitis - Standardised questionnaires on respiratory symptoms. Br 
Med J. 1960:ii. 1665. 
6.CIBA Guest symposium. Terminology, definitions, and classification of 
chronic pulmonary emphysema and related conditions. Thorax. 
1959;14:286-99. 
7.World Health Organisation. Definitions and diagnosis of pulmonary 
diseases with special reference to chronic bronchitis and emphysema. 
Geneva: WHO1961. 
8.American Thoracic Society committee on diagnostic standards for non-
tuberculous disease. Definitions and clarifications on chronic bronchitis, 
asthma, and pulmonary emphysema. Am Rev Respir Dis. 1962;85:762-9. 
9.Lebowitz MD, Burrows B. Comparison of questionnaires: the BMRC 
and NHLI respiratory questionnaires and a new self-completion 
questionnaire. Am Rev Respir Dis. 1976 May;113(5):627-35. 
10.Bergmann MM, Jacobs EJ, Hoffmann K, et al. Agreement of self-
reported medical history: comparison of an in-person interview with a 
self-administered questionnaire. Eur J Epidemiol. 2004;19(5):411-6. 
11.U.S. Department of Health, Education and Welfare: Proceedings, 
First NHLI Epidemiology Workshop. Washington D.C.: Government 
Printing Office1971. 
12.Ferris BG. Epidemiology Standardization Project: II. Recommended 
respiratory disease questionnaires for use with adults and children in 
epidemiological research. Am Rev Respir Dis. 1978 Dec;118:7-53. 
Linda Ekerljung 
 
 
55 
13.Brille D, Bolt W, Greve LH, et al. Notes on the 1962 questionnaire for 
studying chronic bronchitis and pulmonary emphysema. Luxembourg: 
European Community for Coal and Steel1967. 
14.Burney PG, Laitinen LA, Perdrizet S, et al. Validity and repeatability 
of the IUATLD (1984) Bronchial Symptoms Questionnaire: an 
international comparison. Eur Respir J. 1989 Nov;2(10):940-5. 
15.Burney PG, Luczynska C, Chinn S, et al. The European Community 
Respiratory Health Survey. Eur Respir J. 1994 May;7(5):954-60. 
16.Asher MI, Keil U, Anderson HR, et al. International Study of Asthma 
and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir 
J. 1995 Mar;8(3):483-91. 
17.Helsing KJ, Comstock GW, Speizer FE, et al. Comparison of three 
standardized questionnaires on respiratory symptoms. Am Rev Respir 
Dis. 1979 Dec;120(6):1221-31. 
18.Comstock GW, Tockman MS, Helsing KJ, et al. Standardized 
respiratory questionnaires: comparison of the old with the new. Am Rev 
Respir Dis. 1979 Jan;119(1):45-53. 
19.Samet JM. A historical and epidemiologic perspective on respiratory 
symptoms questionnaires. Am J Epidemiol. 1978 Dec;108(6):435-46. 
20.Brogger JC, Bakke PS, Gulsvik A. Comparison of respiratory 
symptoms questionnaires. Int J Tuberc Lung Dis. 2000 Jan;4(1):83-90. 
21.Smeeton NC, Rona RJ, Oyarzun M, et al. Agreement between 
responses to a standardized asthma questionnaire and a questionnaire 
following a demonstration of asthma symptoms in adults. Am J 
Epidemiol. 2006 Feb 15;163(4):384-91. 
22.Pride NB. Revision of the European Community for Coal and Steel 
Questionnaire on Respiratory Symptoms. Eur Respir J. 1989 
Sep;2(8):697-9. 
23.Toren K, Brisman J, Jarvholm B. Asthma and asthma-like symptoms 
in adults assessed by questionnaires. A literature review. Chest. 1993 
Aug;104(2):600-8. 
24.Braman SS. The global burden of asthma. Chest. 2006 Jul;130(1 
Suppl):4S-12S. 
25.GINA. Global Initative for Asthma.  2010; Available from: 
http://www.ginasthma.org. 
26.Anderson HR, Gupta R, Strachan DP, et al. 50 years of asthma: UK 
trends from 1955 to 2004. Thorax. 2007 Jan;62(1):85-90. 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
56 
27.Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in 
the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and 
eczema in childhood: ISAAC Phases One and Three repeat multicountry 
cross-sectional surveys. Lancet. 2006 Aug 26;368(9537):733-43. 
28.Crockett AJ, Cranston JM, Alpers JH. The changing prevalence of 
asthma-like respiratory symptoms in South Australian rural 
schoolchildren. J Paediatr Child Health. 1995 Jun;31(3):213-7. 
29.Magnus P, Jaakkola JJ. Secular trend in the occurrence of asthma 
among children and young adults: critical appraisal of repeated cross 
sectional surveys. BMJ. 1997 Jun 21;314(7097):1795-9. 
30.Toelle BG, Ng K, Belousova E, et al. Prevalence of asthma and 
allergy in schoolchildren in Belmont, Australia: three cross sectional 
surveys over 20 years. BMJ. 2004 Feb 14;328(7436):386-7. 
31.Venn A, Lewis S, Cooper M, et al. Increasing prevalence of wheeze 
and asthma in Nottingham primary schoolchildren 1988-1995. Eur 
Respir J. 1998 Jun;11(6):1324-8. 
32.Zilmer M, Steen NP, Zachariassen G, et al. Prevalence of asthma and 
bronchial hyperreactivity in Danish schoolchildren: no change over 10 
years. Acta Paediatr. 2011 Mar;100(3):385-9. 
33.Ekerljung L, Andersson Å, Sundblad BM, et al. Has the increase in the 
prevalence of asthma and respiratory symptoms reached a plateau in 
Stockholm, Sweden? Int J Tuberc Lung Dis. 2010 Jun;14(6):764-71. 
34.Bjornsson E, Plaschke P, Norrman E, et al. Symptoms related to 
asthma and chronic bronchitis in three areas of Sweden. Eur Respir J. 
1994 Dec;7(12):2146-53. 
35.Cookson JB. Prevalence rates of asthma in developing countries and 
their comparison with those in Europe and North America. Chest. 1987 
Jun;91(6 Suppl):97S-103S. 
36.de Marco R, Locatelli F, Sunyer J, et al. Differences in incidence of 
reported asthma related to age in men and women. A retrospective 
analysis of the data of the European Respiratory Health Survey. Am J 
Respir Crit Care Med. 2000 Jul;162(1):68-74. 
37.McWhorter WP, Polis MA, Kaslow RA. Occurrence, predictors, and 
consequences of adult asthma in NHANESI and follow-up survey. Am Rev 
Respir Dis. 1989 Mar;139(3):721-4. 
38.Barraclough R, Devereux G, Hendrick DJ, et al. Apparent but not real 
increase in asthma prevalence during the 1990s. Eur Respir J. 2002 
Oct;20(4):826-33. 
Linda Ekerljung 
 
 
57 
39.Brögger J, Bakke P, Eide GE, et al. Long-term changes in adult 
asthma prevalence. Eur Respir J. 2003 Mar;21(3):468-72. 
40.Wilson DH, Adams RJ, Tucker G, et al. Trends in asthma prevalence 
and population changes in South Australia, 1990-2003. Med J Aust. 2006 
Mar 6;184(5):226-9. 
41.Lundback B, Ronmark E, Jonsson E, et al. Incidence of physician-
diagnosed asthma in adults--a real incidence or a result of increased 
awareness? Report from The Obstructive Lung Disease in Northern 
Sweden Studies. Respir Med. 2001 Aug;95(8):685-92. 
42.Eagan TM, Brogger JC, Eide GE, et al. The incidence of adult 
asthma: a review. Int J Tuberc Lung Dis. 2005 Jun;9(6):603-12. 
43.Toren K, Hermansson BA. Incidence rate of adult-onset asthma in 
relation to age, sex, atopy and smoking: a Swedish population-based 
study of 15813 adults. Int J Tuberc Lung Dis. 1999 Mar;3(3):192-7. 
44.Ekerljung L, Ronmark E, Larsson K, et al. No further increase of 
incidence of asthma: incidence, remission and relapse of adult asthma in 
Sweden. Respir Med. 2008 Dec;102(12):1730-6. 
45.Toren K, Gislason T, Omenaas E, et al. A prospective study of asthma 
incidence and its predictors: the RHINE study. Eur Respir J. 2004 
Dec;24(6):942-6. 
46.Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its 
Impact on Asthma (ARIA) 2008 update (in collaboration with the World 
Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 
Suppl 86:8-160. 
47.Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic 
rhinitis in Europe. Eur Respir J. 2004 Nov;24(5):758-64. 
48.Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its 
impact on asthma. J Allergy Clin Immunol. 2001 Nov;108(5 Suppl):S147-
334. 
49.Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: 
a longitudinal population-based study. Lancet. 2008 Sep 
20;372(9643):1049-57. 
50.Leynaert B, Bousquet J, Neukirch C, et al. Perennial rhinitis: An 
independent risk factor for asthma in nonatopic subjects: results from the 
European Community Respiratory Health Survey. J Allergy Clin 
Immunol. 1999 Aug;104(2 Pt 1):301-4. 
51.Ronmark E, Perzanowski M, Platts-Mills T, et al. Different 
sensitization profile for asthma, rhinitis, and eczema among 7-8-year-old 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
58 
children: report from the Obstructive Lung Disease in Northern Sweden 
studies. Pediatr Allergy Immunol. 2003 Apr;14(2):91-9. 
52.Ronmark E, Bjerg A, Perzanowski M, et al. Major increase in allergic 
sensitization in schoolchildren from 1996 to 2006 in northern Sweden. J 
Allergy Clin Immunol. 2009 Aug;124(2):357-63, 63 e1-15. 
53.Pallasaho P, Ronmark E, Haahtela T, et al. Degree and clinical 
relevance of sensitization to common allergens among adults: a 
population study in Helsinki, Finland. Clin Exp Allergy. 2006 
Apr;36(4):503-9. 
54.van Ree R, Yazdanbakhsh M. Allergic disorders in African countries: 
linking immunology to accurate phenotype. Allergy. 2007 
Mar;62(3):237-46. 
55.Puccio FA, Lynch NR, Noya O, et al. Importance of including Blomia 
tropicalis in the routine diagnosis of Venezuelan patients with persistent 
allergic symptoms. Allergy. 2004 Jul;59(7):753-7. 
56.Baratawidjaja IR, Baratawidjaja PP, Darwis A, et al. Prevalence of 
allergic sensitization to regional inhalants among allergic patients in 
Jakarta, Indonesia. Asian Pac J Allergy Immunol. 1999 Mar;17(1):9-12. 
57.Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach 
allergy and exposure to cockroach allergen in causing morbidity among 
inner-city children with asthma. N Engl J Med. 1997 May 
8;336(19):1356-63. 
58.Bjerg A, Hedman L, Perzanowski MS, et al. Family history of asthma 
and atopy: in-depth analyses of the impact on asthma and wheeze in 7- to 
8-year-old children. Pediatrics. 2007 Oct;120(4):741-8. 
59.Franzese CB, Burkhalter NW. The patient with allergies. Med Clin 
North Am. 2010 Sep;94(5):891-902. 
60.van Beijsterveldt CE, Boomsma DI. Genetics of parentally reported 
asthma, eczema and rhinitis in 5-yr-old twins. Eur Respir J. 2007 
Mar;29(3):516-21. 
61.Kynyk JA, Mastronarde JG, McCallister JW. Asthma, the sex 
difference. Curr Opin Pulm Med. 2011 Jan;17(1):6-11. 
62.Temprano J, Mannino DM. The effect of sex on asthma control from 
the National Asthma Survey. J Allergy Clin Immunol. 2009 
Apr;123(4):854-60. 
63.Jensen-Jarolim E, Untersmayr E. Gender-medicine aspects in 
allergology. Allergy. 2008 May;63(5):610-5. 
Linda Ekerljung 
 
 
59 
64.Eagan TM, Gulsvik A, Eide GE, et al. The effect of educational level 
on the incidence of asthma and respiratory symptoms. Respir Med. 2004 
Aug;98(8):730-6. 
65.Ellison-Loschmann L, Sunyer J, Plana E, et al. Socioeconomic status, 
asthma and chronic bronchitis in a large community-based study. Eur 
Respir J. 2007 May;29(5):897-905. 
66.Hedlund U, Eriksson K, Ronmark E. Socio-economic status is related 
to incidence of asthma and respiratory symptoms in adults. Eur Respir J. 
2006 Aug;28(2):303-10. 
67.Basagana X, Sunyer J, Kogevinas M, et al. Socioeconomic status and 
asthma prevalence in young adults: the European Community 
Respiratory Health Survey. Am J Epidemiol. 2004 Jul 15;160(2):178-88. 
68.Braback L, Hjern A, Rasmussen F. Social class in asthma and allergic 
rhinitis: a national cohort study over three decades. Eur Respir J. 2005 
Dec;26(6):1064-8. 
69.Ekerljung L, Sundblad BM, Ronmark E, et al. Incidence and 
prevalence of adult asthma is associated with low socio-economic status. 
Clin Respir J. 2010 Jul;4(3):147-56. 
70.Hancox RJ, Milne BJ, Taylor DR, et al. Relationship between 
socioeconomic status and asthma: a longitudinal cohort study. Thorax. 
2004 May;59(5):376-80. 
71.Pallasaho P, Lindstrom M, Polluste J, et al. Low socio-economic 
status is a risk factor for respiratory symptoms: a comparison between 
Finland, Sweden and Estonia. Int J Tuberc Lung Dis. 2004 
Nov;8(11):1292-300. 
72.Wheeler BW, Ben-Shlomo Y. Environmental equity, air quality, 
socioeconomic status, and respiratory health: a linkage analysis of 
routine data from the Health Survey for England. J Epidemiol 
Community Health. 2005 Nov;59(11):948-54. 
73.Farfel A, Tirosh A, Derazne E, et al. Association between 
socioeconomic status and the prevalence of asthma. Ann Allergy Asthma 
Immunol. 2010 Jun;104(6):490-5. 
74.Eagan TM, Bakke PS, Eide GE, et al. Incidence of asthma and 
respiratory symptoms by sex, age and smoking in a community study. Eur 
Respir J. 2002 Apr;19(4):599-605. 
75.Janson C, Chinn S, Jarvis D, et al. Effect of passive smoking on 
respiratory symptoms, bronchial responsiveness, lung function, and total 
serum IgE in the European Community Respiratory Health Survey: a 
cross-sectional study. Lancet. 2001 Dec 22-29;358(9299):2103-9. 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
60 
76.Rönmark E, Andersson C, Nyström L, et al. Obesity increases the risk 
of incident asthma among adults. Eur Respir J. 2005 Feb;25(2):282-8. 
77.Torén K, Blanc PD. Asthma caused by occupational exposures is 
common - a systematic analysis of estimates of the population-
attributable fraction. BMC Pulm Med. 2009;9:7. 
78.Le Moual N, Kauffmann F, Eisen EA, et al. The healthy worker effect 
in asthma: work may cause asthma, but asthma may also influence work. 
Am J Respir Crit Care Med. 2008 Jan 1;177(1):4-10. 
79.Butland BK, Ghosh R, Strachan DP, et al. Job choice and the 
influence of prior asthma and hay fever. Occup Environ Med. 2011 
Jul;68(7):494-501. 
80.Toren K, Brisman J, Olin AC, et al. Asthma on the job: work-related 
factors in new-onset asthma and in exacerbations of pre-existing asthma. 
Respir Med. 2000 Jun;94(6):529-35. 
81.Saarinen K, Karjalainen A, Martikainen R, et al. Prevalence of work-
aggravated symptoms in clinically established asthma. Eur Respir J. 
2003 Aug;22(2):305-9. 
82.Cerveri I, Cazzoletti L, Corsico AG, et al. The impact of cigarette 
smoking on asthma: a population-based international cohort study. Int 
Arch Allergy Immunol. 2012;158(2):175-83. 
83.Sandstrom T, Lundback B. Tobacco smoke: old foe more important for 
asthma than commonly appreciated? Eur Respir J. 2004 Nov;24(5):720-
1. 
84.Ulrik CS, Lange P. Cigarette smoking and asthma. Monaldi Arch 
Chest Dis. 2001 Aug;56(4):349-53. 
85.Kotaniemi JT, Lundback B, Nieminen MM, et al. Increase of asthma in 
adults in northern Finland?--a report from the FinEsS study. Allergy. 
2001 Feb;56(2):169-74. 
86.Viegi G, Pedreschi M, Baldacci S, et al. Prevalence rates of 
respiratory symptoms and diseases in general population samples of 
North and Central Italy. Int J Tuberc Lung Dis. 1999 Nov;3(11):1034-42. 
87.Raherison C, Baldi I, Tunon-De-Lara JM, et al. Asthma phenotypes 
according to the timing of smoking onset in young adults. Int J Tuberc 
Lung Dis. 2003 Jan;7(1):84-92. 
88.Annesi-Maesano I, Oryszczyn MP, Raherison C, et al. Increased 
prevalence of asthma and allied diseases among active adolescent 
tobacco smokers after controlling for passive smoking exposure. A cause 
for concern? Clin Exp Allergy. 2004 Jul;34(7):1017-23. 
Linda Ekerljung 
 
 
61 
89.Arif AA, Delclos GL, Lee ES, et al. Prevalence and risk factors of 
asthma and wheezing among US adults: an analysis of the NHANES III 
data. Eur Respir J. 2003 May;21(5):827-33. 
90.Ronmark E, Lundback B, Jonsson E, et al. Incidence of asthma in 
adults--report from the Obstructive Lung Disease in Northern Sweden 
Study. Allergy. 1997 Nov;52(11):1071-8. 
91.Vesterinen E, Kaprio J, Koskenvuo M. Prospective study of asthma in 
relation to smoking habits among 14,729 adults. Thorax. 1988 
Jul;43(7):534-9. 
92.Vignoud L, Pin I, Boudier A, et al. Smoking and asthma: 
Disentangling their mutual influences using a longitudinal approach. 
Respir Med. 2011 Dec;105(12):1805-14. 
93.Larsson ML, Frisk M, Hallstrom J, et al. Environmental tobacco 
smoke exposure during childhood is associated with increased 
prevalence of asthma in adults. Chest. 2001 Sep;120(3):711-7. 
94.Larsson ML, Loit HM, Meren M, et al. Passive smoking and 
respiratory symptoms in the FinEsS Study. Eur Respir J. 2003 
Apr;21(4):672-6. 
95.Currie GP, Jackson CM, Lipworth BJ. Does bronchial 
hyperresponsiveness in asthma matter? J Asthma. 2004;41(3):247-58. 
96.Hargreave FE, Ryan G, Thomson NC, et al. Bronchial responsiveness 
to histamine or methacholine in asthma: measurement and clinical 
significance. J Allergy Clin Immunol. 1981 Nov;68(5):347-55. 
97.Lowhagen O. [Asthma--a disease difficult to define. Patients can 
receive correct treatment by means of differential diagnosis criteria]. 
Lakartidningen. 2005 Dec 12-31;102(50):3872-3, 5-8. 
98.Busse WW. The relationship of airway hyperresponsiveness and 
airway inflammation: Airway hyperresponsiveness in asthma: its 
measurement and clinical significance. Chest. 2010 Aug;138(2 
Suppl):4S-10S. 
99.Joos GF, O'Connor B, Anderson SD, et al. Indirect airway challenges. 
Eur Respir J. 2003 Jun;21(6):1050-68. 
100.Cockcroft DW. Direct challenge tests: Airway hyperresponsiveness 
in asthma: its measurement and clinical significance. Chest. 2010 
Aug;138(2 Suppl):18S-24S. 
101.Lundback B, Ronmark E, Lindberg A, et al. Asthma control over 3 
years in a real-life study. Respir Med. 2009 Mar;103(3):348-55. 
102.Juusela M, Poussa T, Kotaniemi J, et al. Bronchial 
hyperresponsiveness in a population of north Finland with no previous 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
62 
diagnosis of asthma or chronic bronchitis assessed with histamine and 
methacholine tests. Int J Circumpolar Health. 2008 Sep;67(4):308-17. 
103.Norrman E, Plaschke P, Bjornsson E, et al. Prevalence of bronchial 
hyper-responsiveness in the southern, central and northern parts of 
Sweden. Respir Med. 1998 Mar;92(3):480-7. 
104.Sears MR. Epidemiology of asthma. In: Flenley DC, Petty DL, 
editors. Recent Advances in Respiratory Medicine. Churchill, 
Edinburgh1986. p. 1-11. 
105.Venables KM, Farrer N, Sharp L, et al. Respiratory symptoms 
questionnaire for asthma epidemiology: validity and reproducibility. 
Thorax. 1993 Mar;48(3):214-9. 
106.Abramson MJ, Hensley MJ, Saunders NA, et al. Evaluation of a new 
asthma questionnaire. J Asthma. 1991;28(2):129-39. 
107.Torén K, Brisman J, Järvholm B. Asthma and asthma-like symptoms 
in adults assessed by questionnaires. A literature review. Chest. 1993 
Aug;104(2):600-8. 
108.Larsson L. Incidence and prevalence of asthma - relation to 
differences of asthma drugs between two neighbouring Swedish 
provinces. University of Umeå, Umeå, Sweden, 1995. 
109.Lundbäck B. Asthma, chronic bronchitis and respiratory symptoms: 
prevalence and important determinants. The Obstructive Lung Disease in 
Northern Sweden Study I. . University of Umeå, Umeå, Sweden,  1993. 
110.Ekerljung L, Ronmark E, Lotvall J, et al. Questionnaire layout and 
wording influence prevalence and risk estimates of respiratory symptoms 
in a population cohort. Clin Respir J. 2012 Jan 13. 
111.Beasley R, Weatherall M, Travers J, et al. Time to define the 
disorders of the syndrome of COPD. Lancet. 2009 Aug 
29;374(9691):670-2. 
112.Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of 
asthma in children and adults: the global asthma insights and reality 
surveys. J Allergy Clin Immunol. 2004 Jul;114(1):40-7. 
113.Godard P, Chanez P, Siraudin L, et al. Costs of asthma are 
correlated with severity: a 1-yr prospective study. Eur Respir J. 2002 
Jan;19(1):61-7. 
114.Jansson SA, Rönmark E, Forsberg B, et al. The economic 
consequences of asthma among adults in Sweden. Respir Med. 2007 
Nov;101(11):2263-70. 
Linda Ekerljung 
 
 
63 
115.Juniper EF, Wisniewski ME, Cox FM, et al. Relationship between 
quality of life and clinical status in asthma: a factor analysis. Eur Respir 
J. 2004 Feb;23(2):287-91. 
116.Ekerljung L, Bossios A, Lotvall J, et al. Multi-symptom asthma as an 
indication of disease severity in epidemiology. Eur Respir J. 2011 
Oct;38(4):825-32. 
117.Tough SC, Hessel PA, Ruff M, et al. Features that distinguish those 
who die from asthma from community controls with asthma. J Asthma. 
1998;35(8):657-65. 
118.The EMFUMOSA Study Group. The ENFUMOSA cross-sectional 
European multicentre study of the clinical phenotype of chronic severe 
asthma. European Network for Understanding Mechanisms of Severe 
Asthma. Eur Respir J. 2003 Sep;22(3):470-7. 
119.Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in 
severe persistent asthma. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 
1):1532-9. 
120.Price D, Zhang Q, Kocevar VS, et al. Effect of a concomitant 
diagnosis of allergic rhinitis on asthma-related health care use by adults. 
Clin Exp Allergy. 2005 Mar;35(3):282-7. 
121.GINA report. Global strategy for asthma management and 
prevention.  2009 [2010-08-17]; Available from: 
http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=1561. 
122.British Guideline on the Management of Asthma. Thorax. 2008 
May;63 Suppl 4:iv1-121. 
123.Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998 
Nov;12(5):1209-18. 
124.Global Initiative for Asthma, revision 2006. 2006. 
125.Roche N, Morel H, Martel P, et al. Clinical practice guidelines: 
medical follow-up of patients with asthma--adults and adolescents. 
Respir Med. 2005 Jul;99(7):793-815. 
126.Chen H, Gould MK, Blanc PD, et al. Asthma control, severity, and 
quality of life: quantifying the effect of uncontrolled disease. J Allergy 
Clin Immunol. 2007 Aug;120(2):396-402. 
127.GINA report. Global strategy for asthma management and 
prevention.  2010 [2010-08-17]; 2009:[Available from: 
http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=1561. 
128.Juniper EF. Effect of asthma on quality of life. Can Respir J. 1998 
Jul-Aug;5 Suppl A:77A-84A. 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
64 
129.Bush A, Zar HJ. WHO universal definition of severe asthma. Curr 
Opin Allergy Clin Immunol. 2011 Apr;11(2):115-21. 
130.Hirschberg. Anaphylactoid reaction to aspirin (1902) (classical 
article). Allergy Proc. 1990 Sep-Oct;11(5):249-50; discussion 51-2. 
131.Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to 
nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, 
diagnosis and management: review of the EAACI/ENDA(#) and 
GA2LEN/HANNA*. Allergy. 2011 Jul;66(7):818-29. 
132.Samter M, Beers RF, Jr. Intolerance to aspirin. Clinical studies and 
consideration of its pathogenesis. Ann Intern Med. 1968 May;68(5):975-
83. 
133.Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med. 2004 
Jan;10(1):44-50. 
134.Kim JE, Kountakis SE. The prevalence of Samter's triad in patients 
undergoing functional endoscopic sinus surgery. Ear Nose Throat J. 
2007 Jul;86(7):396-9. 
135.Kasper L, Sladek K, Duplaga M, et al. Prevalence of asthma with 
aspirin hypersensitivity in the adult population of Poland. Allergy. 2003 
Oct;58(10):1064-6. 
136.Chang JE, White A, Simon RA, et al. Aspirin-exacerbated respiratory 
disease: burden of disease. Allergy Asthma Proc. 2012 Mar-
Apr;33(2):117-21. 
137.Picado C, Bioque G, Roca-Ferrer J, et al. Nuclear factor-kappaB 
activity is down-regulated in nasal polyps from aspirin-sensitive 
asthmatics. Allergy. 2003 Feb;58(2):122-6. 
138.Pierzchalska M, Szabo Z, Sanak M, et al. Deficient prostaglandin E2 
production by bronchial fibroblasts of asthmatic patients, with special 
reference to aspirin-induced asthma. J Allergy Clin Immunol. 2003 
May;111(5):1041-8. 
139.Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. 
Eur Respir J. 1990 May;3(5):588-93. 
140.Altman LC, Munk Z, Seltzer J, et al. A placebo-controlled, dose-
ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. 
Montelukast Asthma Study Group. J Allergy Clin Immunol. 1998 
Jul;102(1):50-6. 
141.Cerveri I, Locatelli F, Zoia MC, et al. International variations in 
asthma treatment compliance: the results of the European Community 
Respiratory Health Survey (ECRHS). Eur Respir J. 1999 Aug;14(2):288-
94. 
Linda Ekerljung 
 
 
65 
142.Lötvall J, Ekerljung L, Rönmark EP, et al. West Sweden Asthma 
Study: prevalence trends over the last 18 years argues no recent increase 
in asthma. Respir Res. 2009;10:94. 
143.Pallasaho P, Juusela M, Lindqvist A, et al. Allergic 
rhinoconjunctivitis doubles the risk for incident asthma--results from a 
population study in Helsinki, Finland. Respir Med. 2011 
Oct;105(10):1449-56. 
144.Gu Q, Dillon CF, Burt VL. Prescription drug use continues to 
increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief. 
2010 Sep(42):1-8. 
145.Clatworthy J, Price D, Ryan D, et al. The value of self-report 
assessment of adherence, rhinitis and smoking in relation to asthma 
control. Prim Care Respir J. 2009 Dec;18(4):300-5. 
146.Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion 
of severe asthma exacerbations attributable to inhaled corticosteroid 
nonadherence. J Allergy Clin Immunol. 2011 Oct 20. 
147.Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of 
asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. 
Eur Respir J. 2000 Nov;16(5):802-7. 
148.Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant 
asthma: the need for an integrated approach to define clinical 
phenotypes, evaluate risk factors, understand pathophysiology and find 
novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. 
European Respiratory Society. Eur Respir J. 1999 May;13(5):1198-208. 
149.Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant 
asthma: outcome of a systematic evaluation protocol. Thorax. 2003 
Jul;58(7):561-6. 
150.Robinson DS, Campbell DA, Durham SR, et al. Systematic 
assessment of difficult-to-treat asthma. Eur Respir J. 2003 
Sep;22(3):478-83. 
151.Bae YJ, Kim TB, Jee YK, et al. Severe asthma patients in Korea 
overestimate their adherence to inhaled corticosteroids. J Asthma. 2009 
Aug;46(6):591-5. 
152.Janson C, Chinn S, Jarvis D, et al. Physician-diagnosed asthma and 
drug utilization in the European Community Respiratory Health Survey. 
Eur Respir J. 1997 Aug;10(8):1795-802. 
153.Frew AJ. GA2LEN--The Global Allergy and Asthma European 
Network. Clin Exp Allergy. 2005 Feb;35(2):122-5. 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
66 
154.Liou A, Grubb JR, Schechtman KB, et al. Causative and contributive 
factors to asthma severity and patterns of medication use in patients 
seeking specialized asthma care. Chest. 2003 Nov;124(5):1781-8. 
155.Gamble J, Stevenson M, Heaney LG. A study of a multi-level 
intervention to improve non-adherence in difficult to control asthma. 
Respir Med. 2011 Sep;105(9):1308-15. 
156.Gamble J, Stevenson M, McClean E, et al. The prevalence of 
nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009 Nov 
1;180(9):817-22. 
157.Kandane-Rathnayake RK, Matheson MC, Simpson JA, et al. 
Adherence to asthma management guidelines by middle-aged adults with 
current asthma. Thorax. 2009 Dec;64(12):1025-31. 
158.Laforest L, El Hasnaoui A, Pribil C, et al. Asthma patients' self-
reported behaviours toward inhaled corticosteroids. Respir Med. 2009 
Sep;103(9):1366-75. 
159.Sundberg R, Toren K, Franklin KA, et al. Asthma in men and women: 
treatment adherence, anxiety, and quality of sleep. Respir Med. 2010 
Mar;104(3):337-44. 
160.Hsu J, Peters AT. Pathophysiology of chronic rhinosinusitis with 
nasal polyp. Am J Rhinol Allergy. 2011 Sep-Oct;25(5):285-90. 
161.Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in 
Europe - an underestimated disease. A GA(2) LEN study. Allergy. 2011 
May 24. 
162.Demoly P, Crampette L, Mondain M, et al. Myeloperoxidase and 
interleukin-8 levels in chronic sinusitis. Clin Exp Allergy. 1997 
Jun;27(6):672-5. 
163.Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic 
sinus diseases by measurement of inflammatory mediators. Allergy. 2006 
Nov;61(11):1280-9. 
164.Van Crombruggen K, Zhang N, Gevaert P, et al. Pathogenesis of 
chronic rhinosinusitis: inflammation. J Allergy Clin Immunol. 2011 
Oct;128(4):728-32. 
165.Annesi-Maesano I. Why hasn't human genetics told us more about 
asthma? Int J Tuberc Lung Dis. 2010 May;14(5):521-3. 
166.Apweiler R, Aslanidis C, Deufel T, et al. Approaching clinical 
proteomics: current state and future fields of application in fluid 
proteomics. Clin Chem Lab Med. 2009;47(6):724-44. 
Linda Ekerljung 
 
 
67 
167.Chaerkady R, Letzen B, Renuse S, et al. Quantitative temporal 
proteomic analysis of human embryonic stem cell differentiation into 
oligodendrocyte progenitor cells. Proteomics. 2011 Oct;11(20):4007-20. 
168.Dean RA, Overall CM. Proteomics discovery of metalloproteinase 
substrates in the cellular context by iTRAQ labeling reveals a diverse 
MMP-2 substrate degradome. Mol Cell Proteomics. 2007 Apr;6(4):611-
23. 
169.Neilson KA, Mariani M, Haynes PA. Quantitative proteomic analysis 
of cold-responsive proteins in rice. Proteomics. 2011 May;11(9):1696-
706. 
170.Romero R, Kusanovic JP, Gotsch F, et al. Isobaric labeling and 
tandem mass spectrometry: a novel approach for profiling and 
quantifying proteins differentially expressed in amniotic fluid in preterm 
labor with and without intra-amniotic infection/inflammation. J Matern 
Fetal Neonatal Med. 2010 Apr;23(4):261-80. 
171.Wang H, Chavali S, Mobini R, et al. A pathway-based approach to 
find novel markers of local glucocorticoid treatment in intermittent 
allergic rhinitis. Allergy. 2011 Jan;66(1):132-40. 
172.Roh GS, Shin Y, Seo SW, et al. Proteome analysis of differential 
protein expression in allergen-induced asthmatic mice lung after 
dexamethasone treatment. Proteomics. 2004 Nov;4(11):3318-27. 
173.Zhao J, Yeong LH, Wong WS. Dexamethasone alters 
bronchoalveolar lavage fluid proteome in a mouse asthma model. Int 
Arch Allergy Immunol. 2007;142(3):219-29. 
174.Jeong HC, Lee SY, Lee EJ, et al. Proteomic analysis of peripheral T-
lymphocytes in patients with asthma. Chest. 2007 Aug;132(2):489-96. 
175.Yeo S, Roh GS, Kim DH, et al. Quantitative profiling of plasma 
peptides in asthmatic mice using liquid chromatography and mass 
spectrometry. Proteomics. 2004 Nov;4(11):3308-17. 
176.Ghosh S, Janocha AJ, Aronica MA, et al. Nitrotyrosine proteome 
survey in asthma identifies oxidative mechanism of catalase inactivation. 
J Immunol. 2006 May 1;176(9):5587-97. 
177.Candiano G, Bruschi M, Pedemonte N, et al. Gelsolin secretion in 
interleukin-4-treated bronchial epithelia and in asthmatic airways. Am J 
Respir Crit Care Med. 2005 Nov 1;172(9):1090-6. 
178.Candiano G, Bruschi M, Pedemonte N, et al. Proteomic analysis of 
the airway surface liquid: modulation by proinflammatory cytokines. Am 
J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L185-98. 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
68 
179.Larsen K, Macleod D, Nihlberg K, et al. Specific haptoglobin 
expression in bronchoalveolar lavage during differentiation of 
circulating fibroblast progenitor cells in mild asthma. J Proteome Res. 
2006 Jun;5(6):1479-83. 
180.Larsen K, Malmstrom J, Wildt M, et al. Functional and phenotypical 
comparison of myofibroblasts derived from biopsies and bronchoalveolar 
lavage in mild asthma and scleroderma. Respir Res. 2006;7:11. 
181.Malmstrom J, Tufvesson E, Lofdahl CG, et al. Activation of platelet-
derived growth factor pathway in human asthmatic pulmonary-derived 
mesenchymal cells. Electrophoresis. 2003 Jan;24(1-2):276-85. 
182.Gray RD, MacGregor G, Noble D, et al. Sputum proteomics in 
inflammatory and suppurative respiratory diseases. Am J Respir Crit 
Care Med. 2008 Sep 1;178(5):444-52. 
183.Lindahl M, Stahlbom B, Tagesson C. Newly identified proteins in 
human nasal and bronchoalveolar lavage fluids: potential biomedical 
and clinical applications. Electrophoresis. 1999 Dec;20(18):3670-6. 
184.Lindahl M, Svartz J, Tagesson C. Demonstration of different forms of 
the anti-inflammatory proteins lipocortin-1 and Clara cell protein-16 in 
human nasal and bronchoalveolar lavage fluids. Electrophoresis. 1999 
Apr-May;20(4-5):881-90. 
185.de Torre C, Ying SX, Munson PJ, et al. Proteomic analysis of 
inflammatory biomarkers in bronchoalveolar lavage. Proteomics. 2006 
Jul;6(13):3949-57. 
186.Wu J, Kobayashi M, Sousa EA, et al. Differential proteomic analysis 
of bronchoalveolar lavage fluid in asthmatics following segmental 
antigen challenge. Mol Cell Proteomics. 2005 Sep;4(9):1251-64. 
187.Lindahl M, Irander K, Tagesson C, et al. Nasal lavage fluid and 
proteomics as means to identify the effects of the irritating epoxy 
chemical dimethylbenzylamine. Biomarkers. 2004 Jan-Feb;9(1):56-70. 
188.Lindahl M, Stahlbom B, Tagesson C. Identification of a new potential 
airway irritation marker, palate lung nasal epithelial clone protein, in 
human nasal lavage fluid with two-dimensional electrophoresis and 
matrix-assisted laser desorption/ionization-time of flight. 
Electrophoresis. 2001 May;22(9):1795-800. 
189.Fenn JB, Mann M, Meng CK, et al. Electrospray ionization for mass 
spectrometry of large biomolecules. Science. 1989 Oct 6;246(4926):64-
71. 
190.Makarov A. Electrostatic axially harmonic orbital trapping: a high-
performance technique of mass analysis. Anal Chem. 2000 Mar 
15;72(6):1156-62. 
Linda Ekerljung 
 
 
69 
191.Aebersold R, Goodlett DR. Mass spectrometry in proteomics. Chem 
Rev. 2001 Feb;101(2):269-95. 
192.Wells JM, McLuckey SA. Collision-induced dissociation (CID) of 
peptides and proteins. Methods Enzymol. 2005;402:148-85. 
193.Olsen JV, Macek B, Lange O, et al. Higher-energy C-trap 
dissociation for peptide modification analysis. Nat Methods. 2007 
Sep;4(9):709-12. 
194.Thomas PD, Kejariwal A, Campbell MJ, et al. PANTHER: a 
browsable database of gene products organized by biological function, 
using curated protein family and subfamily classification. Nucleic Acids 
Res. 2003 Jan 1;31(1):334-41. 
195.The Gene Onthology Reference Project.  2012; Available from: 
www.geneontology.org. 
196.Boyle EI, Weng S, Gollub J, et al. GO::TermFinder--open source 
software for accessing Gene Ontology information and finding 
significantly enriched Gene Ontology terms associated with a list of 
genes. Bioinformatics. 2004 Dec 12;20(18):3710-5. 
197.Vedin H. Västergötlands klimat. Sveriges Landskapsklimat Väder 
och Vatten. 2004(4). 
198.Lundbäck B, Nyström L, Rosenhall L, et al. Obstructive lung disease 
in northern Sweden: respiratory symptoms assessed in a postal survey. 
Eur Respir J. 1991 Mar;4(3):257-66. 
199.Pallasaho P, Lundback B, Meren M, et al. Prevalence and risk 
factors for asthma and chronic bronchitis in the capitals Helsinki, 
Stockholm, and Tallinn. Respir Med. 2002 Oct;96(10):759-69. 
200.Lam HT, Ronmark E, Van TTN, et al. Increase in asthma and a high 
prevalence of bronchitis: Results from a population study among adults 
in urban and rural Vietnam. Respir Med. 2010 Oct 26. 
201.Bjerg A, Ekerljung L, Middelveld R, et al. Increased prevalence of 
symptoms of rhinitis but not of asthma between 1990 and 2008 in 
Swedish adults: comparisons of the ECRHS and GA(2)LEN surveys. 
PLoS One. 2011;6(2):e16082. 
202.Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its 
association with chronic rhinosinusitis: the GA2LEN survey in Europe. 
Allergy. 2012 Jan;67(1):91-8. 
203.Rönmark EP, Ekerljung L, Lötvall J, et al. Large scale questionnaire 
survey on respiratory health in Sweden: effects of late- and non-response. 
Respir Med. 2009 Dec;103(12):1807-15. 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
70 
204.Position paper: Allergen standardization and skin tests. The 
European Academy of Allergology and Clinical Immunology. Allergy. 
1993;48(14 Suppl):48-82. 
205.European Community for Coal and Steel. Standardization of lung 
function tests. . Bull Eur Physiopathol Respir. 1983;19(Suppl.):I-93. 
206.Fokkens W, Lund V, Mullol J. European position paper on 
rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007(20):1-136. 
207.Samet JM. Epidemiologic approaches for the identification of 
asthma. Chest. 1987 Jun;91(6 Suppl):74S-8S. 
208.Lundback B, Stjernberg N, Nystrom L, et al. Epidemiology of 
respiratory symptoms, lung function and important determinants. Report 
from the Obstructive Lung Disease in Northern Sweden Project. Tuber 
Lung Dis. 1994 Apr;75(2):116-26. 
209.Lundback B, Stjernberg N, Rosenhall L, et al. Methacholine 
reactivity and asthma. Report from the Northern Sweden Obstructive 
Lung Disease Project. Allergy. 1993 Feb;48(2):117-24. 
210.Meren M, Raukas-Kivioja A, Jannus-Pruljan L, et al. Low 
prevalence of asthma in westernizing countries-myth or reality? 
Prevalence of asthma in Estonia--a report from the "FinEsS" study. J 
Asthma. 2005 Jun;42(5):357-65. 
211.Wilm M, Mann M. Analytical properties of the nanoelectrospray ion 
source. Anal Chem. 1996 Jan 1;68(1):1-8. 
212.Hu Q, Noll RJ, Li H, et al. The Orbitrap: a new mass spectrometer. J 
Mass Spectrom. 2005 Apr;40(4):430-43. 
213.Makarov A, Denisov E, Lange O, et al. Dynamic range of mass 
accuracy in LTQ Orbitrap hybrid mass spectrometer. J Am Soc Mass 
Spectrom. 2006 Jul;17(7):977-82. 
214.Zhang Y, Ficarro SB, Li S, et al. Optimized Orbitrap HCD for 
quantitative analysis of phosphopeptides. J Am Soc Mass Spectrom. 2009 
Aug;20(8):1425-34. 
215.O'Neil SE, Lundback B, Lotvall J. Proteomics in asthma and COPD 
phenotypes and endotypes for biomarker discovery and improved 
understanding of disease entities. J Proteomics. 2011 Dec 10;75(1):192-
201. 
216.Gharib SA, Nguyen EV, Lai Y, et al. Induced sputum proteome in 
healthy subjects and asthmatic patients. J Allergy Clin Immunol. 2011 
Dec;128(6):1176-84 e6. 
217.Cederfur C, Malmstrom J, Nihlberg K, et al. Glycoproteomic 
identification of galectin-3 and -8 ligands in bronchoalveolar lavage of 
Linda Ekerljung 
 
 
71 
mild asthmatics and healthy subjects. Biochim Biophys Acta. 2012 
Sep;1820(9):1429-36. 
218.O'Neil SE, Sitkauskiene B, Babusyte A, et al. Network analysis of 
quantitative proteomics on asthmatic bronchi: effects of inhaled 
glucocorticoid treatment. Respir Res. 2011;12:124. 
219.Bloemen K, Van Den Heuvel R, Govarts E, et al. A new approach to 
study exhaled proteins as potential biomarkers for asthma. Clin Exp 
Allergy. 2011 Mar;41(3):346-56. 
220.Passalacqua G, Ciprandi G, Canonica GW. The nose-lung 
interaction in allergic rhinitis and asthma: united airways disease. Curr 
Opin Allergy Clin Immunol. 2001 Feb;1(1):7-13. 
221.Ghafouri B, Irander K, Lindbom J, et al. Comparative proteomics of 
nasal fluid in seasonal allergic rhinitis. J Proteome Res. 2006 
Feb;5(2):330-8. 
222.Benson LM, Mason CJ, Friedman O, et al. Extensive fractionation 
and identification of proteins within nasal lavage fluids from allergic 
rhinitis and asthmatic chronic rhinosinusitis patients. J Sep Sci. 2009 
Jan;32(1):44-56. 
223.Lundbäck B. Epidemiology of rhinitis and asthma. Clin Exp Allergy. 
1998 Jun;28 Suppl 2:3-10. 
224.Variations in the prevalence of respiratory symptoms, self-reported 
asthma attacks, and use of asthma medication in the European 
Community Respiratory Health Survey (ECRHS). Eur Respir J. 1996 
Apr;9(4):687-95. 
225.Browatzki A, Ulrik CS, Lange P. Prevalence and severity of self-
reported asthma in young adults, 1976-2004. Eur Respir J. 2009 
Nov;34(5):1046-51. 
226.de Marco R, Marcon A, Jarvis D, et al. Prognostic factors of asthma 
severity: a 9-year international prospective cohort study. J Allergy Clin 
Immunol. 2006 Jun;117(6):1249-56. 
227.Cerveri I, Zoia MC, Bugiani M, et al. Inadequate antiasthma drug 
use in the north of Italy. Eur Respir J. 1997 Dec;10(12):2761-5. 
228.Larsson L, Boethius G, Uddenfeldt M. Differences in utilization of 
asthma drugs between two neighbouring Swedish provinces: relation to 
symptom reporting. Eur Respir J. 1993 Feb;6(2):198-203. 
229.Stjernberg N, Eklund A, Nystrom L, et al. Prevalence of bronchial 
asthma and chronic bronchitis in a community in northern Sweden; 
relation to environmental and occupational exposure to sulphur dioxide. 
Eur J Respir Dis. 1985 Jul;67(1):41-9. 
Asthma in West Sweden – a translational study from epidemiology to proteomics 
 
72 
230.Forsberg B, Hansson HC, Johansson C, et al. Comparative health 
impact assessment of local and regional particulate air pollutants in 
Scandinavia. Ambio. 2005 Feb;34(1):11-9. 
231.Gaga M, Papageorgiou N, Yiourgioti G, et al. Risk factors and 
characteristics associated with severe and difficult to treat asthma 
phenotype: an analysis of the ENFUMOSA group of patients based on the 
ECRHS questionnaire. Clin Exp Allergy. 2005 Jul;35(7):954-9. 
232.Le Moual N, Siroux V, Pin I, et al. Asthma severity and exposure to 
occupational asthmogens. Am J Respir Crit Care Med. 2005 Aug 
15;172(4):440-5. 
233.Greenlee KJ, Corry DB, Engler DA, et al. Proteomic identification of 
in vivo substrates for matrix metalloproteinases 2 and 9 reveals a 
mechanism for resolution of inflammation. J Immunol. 2006 Nov 
15;177(10):7312-21. 
234.Lee SH, Rhim T, Choi YS, et al. Complement C3a and C4a increased 
in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care 
Med. 2006 Feb 15;173(4):370-8. 
235.Bryborn M, Adner M, Cardell LO. Psoriasin, one of several new 
proteins identified in nasal lavage fluid from allergic and non-allergic 
individuals using 2-dimensional gel electrophoresis and mass 
spectrometry. Respir Res. 2005;6:118. 
236.Casado B, Pannell LK, Iadarola P, et al. Identification of human 
nasal mucous proteins using proteomics. Proteomics. 2005 
Jul;5(11):2949-59. 
 
  
Linda Ekerljung 
 
 
73 
APPENDIX 
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                                Frågeformulär 
 
 
 
 
 
          Astma, allergi och KOL  
               i Västra Götaland 
 
 
 
 
 
            Vi är tacksamma om Du besvarar alla  
  frågor i bägge frågeformulären, trots att de i vissa  
                             fall kan verka lika. 
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FRÅGEFORMULÄR 
Astma, allergi och KOL i Västra Götaland 2008 
 
 
Besvara frågorna genom att kryssa i lämplig ruta.  
Om Du är osäker om svaret, välj ”Nej/vet ej”  
                      NEJ/          JA 
                 VET EJ 
1.    Är det någon av Dina föräldrar eller syskon som har eller har haft        
       a)  astma     
       b)  allergiska ögon- eller näsbesvär (hösnuva)                    
       c)  kronisk luftrörskatarr (bronkit), KOL eller emfysem      
    
2.    Har Du nu eller har Du haft någon av följande sjukdomar:    
       a)  astma    
       b)  allergiska ögon- eller näsbesvär (hösnuva)                    
       c)  kronisk luftrörskatarr (bronkit), KOL eller emfysem      
       d)  annan lung- eller luftvägssjukdom    
      Om “ja”: 
  Vilken eller vilka? ………….……………………………….………… 
   
    
3.    Har Du av läkare fått diagnosen astma? 
       Om ”ja”: 
   
       Hur gammal var Du när Du fick astma? ……………………år    
    
4.    Har Du av läkare fått diagnosen kronisk luftrörskatarr (bronkit), KOL eller emfysem?      
    
5.    Använder Du astmamediciner (ständigt eller vid behov)?     
    
6.    Har Du nu eller har Du under de senaste 10 åren haft astmabesvär? (Dvs. periodvisa  
       eller anfallsvisa andningsbesvär/andfåddhet, besvären kan uppträda med eller utan   
       hosta och med eller utan pip i bröstet) 
 Om ”ja”: 
 
 
  
 
       Har Du haft sådana besvär under det senaste året (de senaste 12 månaderna)?     
    
7.    Har Du haft långvarig hosta under det senaste året?     
    
8.    Brukar Du hosta upp slem eller har Du slem i bröstet som Du har svårt att få upp?  
 Om ”ja”: 
   
       a)  Har Du fått upp slem de flesta dagar under perioder som varat minst 3 månader?      
       b)  Har Du haft sådana perioder minst 2 år i rad?    
    
9.    Brukar Du ha pip, skrål eller väser det i bröstet då Du andas?     
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                      NEJ/          JA 
                 VET EJ 
10.  Har Du haft pip eller väsningar i bröstet vid något tillfälle under de senaste  
       12 månaderna?   
 Om ”ja”: 
 
 
  
 
 
       a)   Har Du överhuvudtaget varit det minsta andfådd när Du haft pip eller väsningar  
             i bröstet? 
   
       b)   Har Du haft detta pip eller väsande i bröstet när Du inte samtidigt varit förkyld?    
    
11.  Har Du vaknat med trånghetskänsla i bröstet vid något tillfälle under de senaste  
       12 månaderna?   
   
    
12.  Måste Du gå långsammare än jämnåriga på slät mark på grund av andfåddhet?     
    
13.  Brukar Du bli andfådd, få pip i bröstet eller hostattacker:      
 a)   vid ansträngning     
       b)   i kyla      
       c)   vid ansträngning utomhus i kallt väder       
       d)   i dammiga miljöer    
       e)   av cigarett-  eller tobaksrök     
       f)    av bilavgaser    
 g)   av starka dofter (parfym, kryddoft, trycksvärta, rengöringsmedel, blommor etc)     
       h)   av pollen från växter som gräs och/eller träd     
        i)   vid kontakt med pälsdjur (katt, hund, häst eller andra pälsdjur)      
    
14.  Har Du någon gång reagerat med andningssvårigheter inom 3 timmar efter att ha tagit 
       en värktablett?  
       Om ”ja”: 
 
 
  
 
       Kommer Du ihåg namnet på medicinen? ………….…………………………………     
    
15.  Har Du nästäppa mer eller mindre ständigt?     
       Oavsett ”ja” eller ”nej”:    
       Har Du snuva mer eller mindre ständigt?    
    
16.  Är Du rökare? (Som rökare räknas även de som röker enstaka cigaretter eller  
       pipstopp per vecka och de som slutat röka under det senaste 12 månaderna.) 
       Om ”ja”:  
 
 
  
 
 Hur många cigaretter röker Du per dag? 
Mindre än 5                5 – 14              15 – 24              25 eller mer   
   
       Om ”nej”:     
       Har Du tidigare varit rökare och slutat röka för mer än ett år sedan?     
       Om Du är eller har varit rökare:    
       Hur gammal var Du när Du började röka?                                             .…………….år     
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                      NEJ/          JA 
                 VET EJ 
 
17. Är Du yrkesverksam? 
 Om ”ja”:  
   
 Arbetar Du heltid?     
    
18.  Vilket har varit Ditt huvudsakliga yrke eller sysselsättning? 
 
       …….................……............................................................................... 
   
 Hur många år sammanlagt har Du arbetat i detta yrke?                        ..................…år     
    
19. Har Du nu något annat yrke eller sysselsättning (är studerande, arbetssökande,     
      hemmafru, förtidspensionerad, har ålderspension osv.)?    
     a) Vilket?  ………….……………………………….…………………………    
     b) Sedan hur många år?                                                                             ……………..år    
    
20. När arbetet blir kroppsligt besvärande, har Du då möjlighet att dra ner på takten eller 
 arbeta annorlunda, så att besvären minskar? 
 
   
  Ja, ofta  Ja, ibland  Nej, sällan  Nej, aldrig/nästan aldrig    
    
21. När arbetet blir psykiskt påfrestande, har Du då möjlighet att påverka det Du gör, så att 
 påfrestningen minskar? 
 
   
  Ja, ofta  Ja, ibland  Nej, sällan  Nej, aldrig/nästan aldrig    
    
22. Känner Du Dig utvilad och återhämtad när Du börjar arbetet? 
 
   
  Ja, ofta  Ja, ibland  Nej, sällan  Nej, aldrig/nästan aldrig    
    
23. Hur stor är Din arbetsförmåga i Ditt nuvarande arbete (förutsatt heltidsarbete och uttryckt i 
 procent)  
  ……………………….% 
 Frågan syftar att ta reda på Din totala arbetsförmåga oavsett Din arbetstid. 
 Om Du arbetar 30 timmar i veckan men skulle orka arbeta 40 timmar, ange  
 då 100% som svar. 
 Om Du arbetar 40 timmar i veckan, men orkar egentligen bara 30 timmar i veckan, ange 
 då 75% som svar. 
   
    
24. Har Du varit sjukskriven vid något eller några tillfällen under de senaste 12 månaderna? 
 Om Du är sjukskriven just nu, räkna inte med den nuvarande sjukskrivningsperioden.  
   
 Om ”ja”: 
  1 – 7 dagar     8 – 30 dagar  2 – 3 månader   4 – 12 månader  
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                      NEJ/          JA 
                 VET EJ 
 
25. Har Du varit sjukskriven p g a andningsbesvär under de senaste 12 månaderna?    
    
26. Har Du någon gång ändrat arbetsuppgifter p g a astma eller andra andningsbesvär?    
 Om ”ja”: 
 Vilket år? ……………………….. 
 Vilket yrke hade Du då?………………………………. 
   
    
27. Har Du någon gång ändrat arbetsuppgifter p g a andra hälsoskäl?    
 Om ”ja”: 
 Vilket år? …………………….… 
 Vilket yrke hade Du då?……………………………… 
   
    
28. Hur störd är Du när Du befinner Dig hemma av luftföroreningar utomhus (från trafik,  
 industrier etc) om Du har Dina fönster öppna? (Om Du inte alls känner Dig störd välj 0, 
  om Du känner Dig oerhört störd välj 10 och om Du känner Dig någonstans däremellan 
 välj en siffra mellan 0 och 10)  
 
0    1    2    3    4    5    6    7    8    9    10 
 Inte alls störd  Outhärdlig störning 
   
    
29. Har Du under de senaste 10 åren någon gång haft en vattenskada i Din bostad? 
 
   
 Om ”ja”:  
 Vilket år? …………………………………….. 
   
    
30. Har Du under de senaste 10 åren någon gång haft en synlig mögelskada i Din bostad? 
 
   
 Om ”ja”:  
 Vilket år? …………………………………….. 
   
    
31.  Har Du varit mycket utsatt för damm, gaser eller rök i arbetet?     
    
32.  Hur många gånger per vecka (i genomsnitt) äter Du fisk?  ……………………….……    
    
33.  Hur många gånger per vecka tränar eller sportar Du så mycket att Du blir svettig  
       eller andfådd, eller går på långpromenad, skidåkning eller motsvarande? …………... 
 
 
  
    
34.  Bodde Du på landsbygden (dvs inte stad eller tätort) under Dina fem första levnadsår?           
       Hade Din familj jordbruk under Dina fem första levnadsår?    
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Besvara frågorna genom att kryssa i rätt alternativ.  
                          NEJ     JA 
   X 
     X   Om Du är osäker vid ”nej-ja-frågor”, välj ”nej”-rutan. 
      
 
                                       NEJ     JA 
  1. Har Du haft pip eller har det väst i bröstet vid något tillfälle under       
 de senaste 12 månaderna?      
 OM SVARET ÄR ”NEJ” GÅ TILL FRÅGA 2 OM ”JA” GÅ TILL FRÅGA 1.1     
                                                                                                                        NEJ     JA 
      1.1 Har Du överhuvudtaget varit det minsta andfådd när Du haft detta pipande ljud?                     
  
                 NEJ     JA 
      1.2 Har Du haft detta pip eller väsande i bröstet när Du inte samtidigt varit förkyld?      
  
   
                NEJ    JA 
  2. Har Du vaknat med en trånghetskänsla i bröstet vid något tillfälle under      
      de senaste 12 månaderna? 
      
 
           NEJ    JA 
  3. Har Du vaknat av andnödsattack vid något tillfälle       
       de senaste 12 månaderna? 
  
 
                                    NEJ    JA 
  4. Har Du vaknat av hostattack vid något tillfälle de senaste 12 månaderna?      
 
  
  5.  Brukar Du under vintern få upp slem från bröstet nästan varje dag           NEJ    JA 
       under åtminstone tre månader varje år?      
 
           NEJ     JA 
  6. Har Du någonsin haft astma?      
 OM ”NEJ” GÅ TILL FRÅGA 7   OM ”JA” GÅ TILL FRÅGA 6.1     
                                                                                           ÅLDER 
                               6.1 Hur gammal var Du när Du hade Ditt första astmaanfall?     
                 (Om osäker, ange Din bästa gissning!)   
           NEJ    JA 
                                  6.2 Har Du någonsin varit inlagd på sjukhus       
                                           på grund av astma? 
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                                                                                                                                       NEJ    JA 
                                   6.3 Har Du haft något astmaanfall under      
                                      de senaste 12 månaderna?  
 
 
   
               NEJ    JA 
                                   6.4  Tar Du för närvarande någon astmamedicin, inklusive      
                                   inhalatorer, sprejer eller tabletter? 
                          
 
  
                                                                                                                 NEJ   JA                                                                                                                                                                                                                                                                                                                                                                      
  7. Har Du hösnuva eller någon annan allergisk snuva?      
 OM ”NEJ” GÅ TILL FRÅGA 8 OM ”JA” GÅ TILL FRÅGA 7.1     
                                                             NEJ     JA 
               7.1 Har Du haft problem med allergisk snuva      
                          under de senaste 12 månaderna? 
   
           NEJ    JA 
             7.2 Har Du någonsin haft problem med allergisk snuva under      
              mer än 4 dagar under en enskild vecka?          
             
                                                                                                                                                                  NEJ     JA 
           7.3 Om ”ja”,  hände detta under mer än 4 veckor i sträck?      
                                                                                                                                                     NEJ     JA 
           7.4 Har Du klåda eller irritation i ögonen samtidigt med Dina näsbesvär?      
 
 
 
                                    NEJ    JA 
  8. Har Du varit täppt i näsan i mer än 12 veckor under de senaste 12 månaderna?      
                  
              NEJ    JA 
  9. Har Du haft värk eller tryck runt pannan, näsan eller ögonen i       
      mer än 12 veckor under de senaste 12 månaderna? 
  
                                                                                                         
 
                NEJ     JA 
  10. Har Du haft missfärgat nässekret (snor) eller missfärgat slem i halsen      
        i mer än 12 veckor under de senaste 12 månaderna? 
 
 
                                         NEJ     JA 
  11. Har Ditt luktsinne varit nedsatt eller borta i mer än 12 veckor      
        under de senaste 12 månaderna?  
 
              NEJ     JA 
   12. Har en läkare någon gång sagt att Du har                                             
         kronisk bihåleinflammation?  
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                                           NEJ     JA 
  13. Har Du någonsin under minst 6 månader haft besvär av återkommande kliande utslag?           
 OM ”NEJ” GÅ TILL FRÅGA 14 OM ”JA” GÅ TILL FRÅGA 13.1     
             NEJ    JA 
                            13.1 Har Du haft det kliande utslaget under de senaste 12 månaderna?      
 
      
           
   NEJ     JA      
                            13.2 Drabbar detta endast Dina händer?      
 
  
                             NEJ     JA 
   14. Har Du någonsin haft eksem eller någon form av hudallergi?      
 
         
 15. Har Du någon gång haft svårt att andas inom 3 timmar efter att Du intagit                       NEJ      JA            
         smärtstillande läkemedel?      
 OM ”NEJ” GÅ TILL FRÅGA 16  OM ”JA” GÅ TILL FRÅGA 15.1     
                                               
                            15.1 Var vänlig skriv ner läkemedlets namn…………………………   
  
 
                     NEJ     JA 
  16. Har Du någonsin rökt under minst ett års tid?      
[”JA” betyder minst en cigarett om dagen eller en cigarr i veckan under minst ett år]     
   OM ”NEJ” GÅ TILL FRÅGA 17 OM ”JA” GÅ TILL FRÅGA 16.1     
                      ÅLDER 
                                                              16.1 Hur gammal var Du när Du började röka?     
 
                             NEJ     JA 
                                                              16.2 Har Du rökt alls under sista månaden?      
  OM ”JA” GÅ TILL FRÅGA 16.3 OM ”NEJ” GÅ TILL 16.2.1     
                                                           ÅLDER 
                                                          16.2.1 Hur gammal var Du när Du slutade röka?     
 
 
         Cigaretter per dygn 
           16.3 I genomsnitt, hur mycket röker (rökte) Du?     
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          17. Är Du för närvarande:                                               Kryssa bara i  en ruta!                    
anställd  1.   
egen-företagare 2.   
arbetslös 3.   
sjukskriven, sjukbidrag 4.   
hemarbetande full tid 5.   
studerande, full tid 6.   
pensionerad 7.   
övrigt 8.   
 
    18. Arbetar Du för närvarande:                  NEJ        JA 
        a. inom sjukvården (t.ex. som sjuksköterska, undersköterska,        
            medicintekniker, läkare, ambulanssjukvårdare eller liknande)? 
 
    
 NEJ  JA 
b. i ett jobb som huvudsakligen innefattar någon typ av arbete     
                   med rengörning eller städning 
 
          cm 
  19. Hur lång är Du?     
 
           kg 
  20. Hur mycket väger Du?     
  
 
              DAG      MÅNAD            ÅR 
  21. Ange Ditt födelsedatum                                                                               19     
 
 
              DAG      MÅNAD           ÅR 
  22. Ange dagens datum       20    
 
 
   MAN   KVINNA 
  23. Är Du man eller kvinna?     
 
 
  24. Vad har Du för postnummer?       
   
        ÅR 
  25. Hur många år har du bott på nuvarande adress?    
 
                        TIMMAR 
  26. Hur lång tid per dygn vistas Du vanligtvis i bostaden?    
 
 
  27. Hur ofta brukar Du uppleva luften i Ditt bostadsområde som irriterande? 
              Kryssa bara i en ruta! 
                                                                    Dagligen/nästan dagligen 1.   
                                                                                   Ibland/periodvis 2.   
                                                                                        Sällan/aldrig 3.   
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  28. Hur besvärande är avgaserna från trafiken i Ditt bostadsområde? 
                  Kryssa bara i en ruta! 
                                                                                              Inget/lite 1.   
                                                                                                  Något 2.   
                                                                                                Mycket 3.   
 
                       MINUTER 
  29. Hur lång tid reser/går Du omgiven av stadstrafik en vanlig vardag?    
 
  30. Har något av följande konstaterats i Din bostad de senaste 12 månaderna? 
                           NEJ     JA 
   a  Vattenskador/fuktskador inomhus på väggar, golv, eller tak?      
   b  ”Buckliga” plastmattor, gulnade plastmattor eller svartnad parkett?     
   c  Synlig mögelväxt på väggar, golv eller i taket?     
 
 
  31. Vilken är den högsta utbildning Du har?                                 Kryssa bara i en ruta!                    
Gått i skola mindre än 5 år 1.   
Folkskola eller grundskola 2.   
Realskola eller flickskola 3.   
2-årigt gymnasium eller yrkesskola 4.   
3-4-årigt gymnasium 5.   
Universitet eller högskola, 2,5 år eller kortare (mindre än 120 p) 6.   
Universitet eller högskola, 3 år eller längre (mer än 120 p) 7.   
 
                           NEJ     JA 
  32. Har Du någon gång haft ett arbete där Du utsatts för gas, rök      
        eller damm? 
 
                           NEJ     JA 
  33. Har en läkare någon gång sagt att Du har kroniskt obstruktiv     
        lungsjukdom (KOL)? 
 
 
  34. Frågor om sömn och sömnkvalité: 
 Siffrorna betyder 1: aldrig eller sällan   
  2: mindre än en gång i veckan   
 3: 1 till 2 ggr i veckan   
  4: 3 till 5 ggr i veckan   
  5: nästan varje dag eller natt 
 
         Hur ofta har det hänt under de senaste månaderna: 
     Ringa in rätt svar 
 a. att Du snarkar högt och störande?  1  2  3 4  5 
 
 b. att Du har svårt att somna på kvällen?  1  2  3 4  5 
 
 c. att Du vaknar flera gånger under natten?  1  2  3 4  5 
 
 d. att Du känner Dig sömnig under dagen  1  2  3 4  5 
 
 e. att Du vaknar för tidigt och kan inte somna om? 1 2  3 4  5  
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  35. Tar Du för närvarande medicin för 
                                  NEJ     JA 
högt blodtryck 1     
KOL 2     
sockersjuka/diabetes 3     
sömnbesvär 4     
 
 
       NEJ     JA 
  36. Har Du någonsin snusat dagligen under minst 6 månader?       
                    NEJ     JA 
                                                              36.1 Om ”ja” snusar Du fortfarande?      
 
      NEJ     JA 
  37. Använder Du tuggtobak, nikotinplåster eller nikotintuggummi?      
 
 
  38. Hur ofta brukar Du motionera så mycket att Du blir andfådd eller börjar svettas? 
                                                                                   Kryssa bara i  en ruta!                    
varje dag 1.  
4-6 gånger per vecka 2.  
2-3 gånger per vecka 3.  
en gång i veckan 4.  
en gång i månaden 5.  
mindre än en gång i månaden 6.  
aldrig 7.  
 
39. Hur många timmar per vecka brukar Du motionera så mycket att Du blir andfådd 
   eller börjar svettas? 
                                                                                   Kryssa bara i en ruta! 
aldrig 1.  
ungefär ½ timma 2.  
ungefär 1 timma 3.  
ungefär 2-3 timmar 4.  
ungefär 4-6 timmar 5.  
7 timmar eller mer 6.  
 
 
 
      40. Får vi ta kontakt med Dig igen för ytterligare hjälp                   NEJ      JA                                                                                                                                                                          
                        med projektet eller för att be om ytterligare information?       
 
                    40.1 Om ”ja”,  på vilket telefonnummer kan vi lättast nå Dig?  
 
                                      
 
 
 
 Tack för hjälpen! 
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